

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07747 A1

(51) International Patent Classification⁷: **A61K 38/00**,
C12N 9/12, C12Q 1/48

(21) International Application Number: PCT/US01/22347

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/219,244 18 July 2000 (18.07.2000) US

(71) Applicant (for all designated States except US): **JOSLIN
DIABETES CENTER, INC.** [US/US]; One Joslin Place,
Boston, MA 02115 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KING, George, Liang**
[US/US]; 101 Sentre Street, Dover, MA 02030 (US).

(74) Agents: **MYERS, P., Louis et al.**; Fish & Richardson P.C.,
225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 02/07747 A1

(54) Title: METHODS OF MODULATING FIBROSIS

(57) Abstract: The invention features method fo modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

METHODS OF MODULATING FIBROSIS

Related Applications

This application claims the benefit of U.S. Provisional application No. 60/219,244, filed on July 18, 2000, the contents of which are incorporated herein by reference in their entirety.

Federally Sponsored Research Or Development

The U.S. Government may have certain rights in this invention pursuant to Grant No. EY5110 awarded by the National Institutes of Health to George L. King.

Background

Angiogenesis and fibrosis are key components in development, growth, wound healing, and regeneration (Klagsbrun & D'Amore, (1991) *Annu. Rev. Physiol.* 53, 217-239). In addition, these processes commonly occur together in many disease states where neovascularization is believed to initiate the pathological cascade, including proliferative diabetic retinopathy (Aiello et al. (1998) *Diabetes Care* 21, 143-156), rheumatoid arthritis (Firestein (1999) *J. Clin. Invest.* 103, 3-4), and age-related macular degeneration (Lopez et al. (1996) *Invest. Ophthalmol. & Visual Sci.* 37, 855-868).

Vascular endothelial growth factor (VEGF) is expressed as a family of peptides of 121, 145, 165, 189, and 206 amino acid residues. Its expression is induced by hypoxia and is essential in the vasculogenesis process during development. Several receptors have been shown to mediate the action of VEGF, and most of them belong to the tyrosine kinase receptor family (Petrova et al. (1999) *Exp. Cell Res.* 253, 117-130). Upon the binding of VEGF to its receptors, multiple signaling cascades are activated, including the tyrosine phosphorylation of phospholipase C γ , elevation of intracellular calcium and diacylglycerol, activation of protein kinase C (PKC), and extracellular signal-regulated kinase (MAPK/ERK) for endothelial cell proliferation. In addition, VEGF also stimulates activation of phosphatidylinositol (PI) 3-kinase leading to Akt/PKB activation and possibly enhancing endothelial cell survival.

Connective tissue growth factor (CTGF) is a potent and ubiquitously expressed growth factor that has been shown to play a unique role in fibroblast proliferation, cell adhesion, and

the stimulation of extracellular matrix production (Frazier et al. (1996) *J. Invest. Dermatol.* 107, 404-411; Kireeva et al. (1997) *Exp. Cell Res.* 233, 63-77). The 38-kDa protein was originally identified in conditioned medium from human umbilical vein endothelial cells, and the expression was shown to be selectively stimulated by transforming growth factor- β (TGF- β) in cultured fibroblasts. Due to its mitogenic action on fibroblasts and its ability to induce the expression of the extracellular matrix molecules, collagen type I, fibronectin, and integrin $\alpha 5$, CTGF is supposed to play an important role in connective tissue cell proliferation and extracellular matrix deposition as one of the mediators of TGF- β . CTGF also seems to be an important player in the pathogenesis of various fibrotic disorders, since it was shown to be overexpressed in scleroderma, keloids, and other fibrotic skin disorders (Igarashi et al. (1996) *J. Invest. Dermatol.* 106, 729-733), as well as in stromal rich mammary tumors, and in advanced atherosclerotic lesions. Recently, the integrin $\alpha 5 \beta 3$ has been reported to serve as a receptor on endothelial cells for CTGF-mediated endothelial cell adhesion, migration, and angiogenesis (Babic et al. (1999) *Mol. Cell. Biol.* 19, 2958-2966).

Besides TGF- β , the expression of CTGF is reported to be regulated by dexamethasone in BALB/c 3T3 cells, high glucose in human mesangial cells, kinin in human embryonic fibroblasts, factor VIIa, and thrombin in WI-38 fibroblasts, tumor necrosis factor α in human skin fibroblast, and cAMP in bovine endothelial cells (Dammeier et al. (1998) *J. Biol. Chem.* 273, 18185-18190; Murphy et al. (1999) *J. Biol. Chem.* 274, 5830-5834; Ricupero et al. (2000) *J. Biol. Chem.* 275, 12475-12480; Pendurthi et al. (2000) *J. Biol. Chem.* 275, 14632-14641; Abraham et al. (2000) *J. Biol. Chem.* 275, 15220-15225; Boes et al. (1999) *Endocrinology* 140, 1575-1580).

Summary

The invention is based, in part, on the discovery that VEGF can regulate connective tissue growth factor (CTGF), e.g., through the PI3 Kinase-Akt pathway. CTGF is a potent diffusible growth factor which regulates extracellular matrix deposition and connective tissue cell proliferation. CTGF is a potent activator of fibrosis, angiogenesis, and extracellular matrix production. Modulation of the levels of CTGF via the VEGF pathway, e.g., by modulation of a VEGF activity, e.g., a VEGF signaling activity, e.g., a VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt 4, neuropilin-1 (NP-1), tie, or tie2 activity;

modulation of PI3-kinase; or modulation of Akt can thereby stimulate or alternatively reduce fibrosis and/or angiogenesis. Accordingly, one aspect of the invention features methods of modulating fibrosis. Another aspect features methods of modulating angiogenesis.

In one aspect, the invention features a method of decreasing fibrosis in a tissue, e.g., a skin, lung, retinal, renal, cardiac, or liver tissue of a subject, e.g., a human or non-human animal, by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity. In a preferred embodiment, the method includes identifying a subject in need of decreased fibrosis, e.g., a subject having a fibrotic disorder, e.g., a disorder described herein.

In a preferred embodiment, VEGF signaling is decreased by administering an agent that inhibits a component of the VEGF signal transduction pathway, e.g., an agent that decreases VEGF activity, decreases VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt4, NP-1, tie, or tie2 activity; decreases PI3-kinase activity; decreases an Akt activity; decreases an Erk activity.

In a preferred embodiment, KDR, Flt-4, Flt-1 or neuropilin activity is decreased.

In a preferred embodiment, the subject has a disorder related to unwanted or excessive fibrosis. In some embodiments, fibrosis is exhibited in, e.g., skin, liver, kidney, cardiac, or lung tissue. The disorder can be caused by scarring, e.g., keloid formation. Examples of other disorders related to unwanted or excessive fibrosis include, but are not limited to, scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis, e.g., diffuse interstitial pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; a disease of the kidney, e.g., glomerular sclerosis, renal tubulointerstitial fibrosis, or progressive renal disease; atherosclerotic plaques, e.g., restenosis; inflammatory bowel disease; Crohn's disease; arthritic joints, e.g., rheumatoid arthritis; cancer, e.g., invasive breast carcinoma, stromal rich mammary tumors, dermatofibromas, angioliipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture; macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal

fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments; or macular degeneration, e.g., age-related macular degeneration;

The method includes administering an agent which decreases CTGF activity or expression. In a preferred embodiment, the agent is an agent described herein that decreases a VEGF signaling activity.

In a preferred embodiment, CTGF activity or expression is decreased in an endothelial cell.

In a preferred embodiment, CTGF activity or expression is decreased in a pericyte.

An agent which decreases CTGF activity can be one or more of: an agent which decreases the level or activity of VEGF, e.g., an agent which inhibits VEGF interaction with a VEGF receptor (VEGFR), e.g., flt4, fltl, NP-1 tie, tie-2, and/or KDR/flk1; an agent which inhibits VEGF receptor activation; an agent which disrupts a VEGF-VEGFR complex; an agent which inhibits PI3 Kinase activity; an agent that inhibits VEGFR binding to p85, the catalytic subunit of PI3 kinase; an agent which inhibits AKT kinase activity.

In a preferred embodiment, VEGF is inhibited. VEGF can be inhibited by administering an agent which inhibits VEGF gene expression, protein production levels and/or activity. An agent which inhibits VEGF can be one or more of: a VEGF binding protein, e.g., a soluble VEGF binding protein, e.g., the ectodomain of a VEGF-receptor; an antibody that specifically binds to the VEGF protein, e.g., an antibody that disrupts VEGF's ability to bind to its natural cellular target, e.g., disrupts VEGF's ability to bind to a VEGF receptor, e.g., Fltl (VEGFR1), Flkl/KDR (VEGFR2), NP-1, tie, tie-2, or Flt4 (VEGFR3); an antibody that disrupts the ability of a VEGF receptor to bind to VEGF; an antibody or small molecule which disrupts a complex formed by VEGF and its receptor; a mutated inactive VEGF or fragment which binds to a VEGF receptor but does not activate the receptor; a VEGF nucleic acid molecule which can bind to a cellular VEGF nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF ribozyme; an agent which decreases VEGF gene expression, e.g., a small molecule which binds the promoter of VEGF. In another preferred embodiment, VEGF is inhibited by decreasing the level of expression of an endogenous VEGF gene, e.g., by decreasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene can be decreased by: altering the regulatory sequences of the endogenous VEGF gene, e.g., by the

addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, the antibody which binds VEGF is a monoclonal antibody, e.g., a humanized chimeric or human monoclonal antibody.

In a preferred embodiment, VEGF interaction with its receptor is inhibited. An agent which inhibits a VEGF receptor, e.g., Flt1 (VEGFR1), Flk1/KDR (VEGFR2), neuropilin-1, tie, tie-2, or Flt4 (VEGFR3), can be one or more of: a VEGF receptor nucleic acid molecule which can bind to a cellular VEGF receptor nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF receptor ribozyme; an agent which decreases VEGF receptor gene expression, e.g., a small molecule which binds the promoter of a VEGF receptor. In another preferred embodiment, a VEGF receptor is inhibited by decreasing the level of expression of an endogenous VEGF receptor gene, e.g., by decreasing transcription of an VEGF receptor gene. In a preferred embodiment, transcription of a VEGF receptor gene can be decreased by: altering the regulatory sequences of an endogenous VEGF receptor gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA binding site for a transcriptional activator); as well as agents described above.

In a preferred embodiment, PI3 kinase is inhibited. An agent which inhibits PI3-kinase activity can be one or more of: a small molecule which inhibits PI3-kinase activity, e.g., LY294002; a protein or peptide that inhibits PI3 kinase activity, e.g., a PI3 kinase binding protein which binds to PI3-kinase but does not activate the enzyme, or a dominant negative form of p85; an antibody that specifically binds to the PI3-kinase protein, e.g., an antibody that disrupts PI3-kinase's catalytic activity or an antibody that disrupts the ability of cellular receptors to activate PI3-kinase; a PI3 kinase nucleic acid molecule which can bind to a cellular PI3 kinase nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or PI3-kinase ribozyme; an agent which decreases PI3-kinase gene expression, e.g., a small molecule which binds the promoter of PI3-kinase. In another preferred embodiment, PI3-kinase is inhibited by decreasing the level of expression of an endogenous PI3-kinase gene, e.g.,

by decreasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene can be decreased by: altering the regulatory sequences of the endogenous PI3-kinase gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, PI3-kinase activity is inhibited by a specific small molecule inhibitor, e.g., wortmannin or LY294002.

In another preferred embodiment, AKT kinase is inhibited. An agent which inhibits AKT kinase activity can be one or more of: a specific small molecule which inhibits AKT activity; an AKT binding protein which binds to AKT but does not activate the enzyme; an antibody that specifically binds to the AKT protein, e.g., an antibody that disrupts AKT's catalytic activity or an antibody that disrupts the ability of the AKT PH domain to sense activating second messengers, e.g., phosphoinositides; a mutated inactive AKT or fragment which binds to a AKT receptor but does not activate the receptor; an AKT nucleic acid molecule which can bind to a cellular AKT nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or AKT ribozyme; an agent which decreases AKT gene expression, e.g., a small molecule which binds the promoter of AKT. In another preferred embodiment, AKT is inhibited by decreasing the level of expression of an endogenous AKT gene, e.g., by decreasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene can be decreased by: altering the regulatory sequences of the endogenous AKT gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

In one embodiment, increasing a PKC activity, e.g., a PKC α , PKC β 1, PKC β 2, or PKC γ activity, can inhibit PI3 kinase or Akt, thus decreasing CTGF expression or activity. The agent which increases the level of PKC activity can be one or more of the following: a small molecule which stimulates PKC activity, e.g., PMA; a PKC polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof; an agent which increases PKC nucleic acid expression; e.g., a small molecule which binds to the promoter region of PKC. In a preferred embodiment, PKC levels are

increased by administering, e.g., introducing, a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PKC coding region; a promoter sequence, e.g., a promoter sequence from a PKC gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PKC gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PKC gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PKC protein is increased by increasing the level of expression of an endogenous PKC gene, e.g., by increasing transcription of the PKC gene. In a preferred embodiment, transcription of the PKC gene is increased by: altering the regulatory sequence of the endogenous PKC gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PKC gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is inhibited. An agent which inhibits Erk kinase activity can be one or more of: a specific small molecule which inhibits Erk activity; a Erk binding protein which binds to Erk but does not activate the enzyme; an antibody that specifically binds to the Erk protein, e.g., an antibody that disrupts Erk's catalytic activity; a mutated inactive Erk or fragment which binds to a Erk receptor but does not activate the receptor; a Erk nucleic acid molecule which can bind to a cellular Erk nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or Erk ribozyme; an agent which decreases Erk gene expression, e.g., a small molecule which binds the promoter of Erk. In another preferred embodiment, Erk is inhibited by decreasing the level of expression of an endogenous Erk gene, e.g., by decreasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene can be decreased by: altering the regulatory sequences of the endogenous Erk gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

Another aspect of the invention features methods of reducing angiogenesis by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity by any of the methods described herein. In preferred embodiments, angiogenesis is reduced to, e.g., treat a disorder related to excessive angiogenesis, e.g., tumor growth, tumor metastasis, arthritis, retinal neovascular disease, and retinal ischemia. The method includes administering an agent which decreases CTGF transcription or activity by inhibiting a component of the VEGF signaling pathway, e.g., by any of the agents mentioned above.

Another aspect of the invention features methods of increasing fibrosis.

In a preferred embodiment, the invention features a method of treating disorders related to insufficient fibrosis. The disorder can be the result of an injury. The disorder can be due to a genetic deficiency, a second physiological disorder or disease, or an environmental insult. In a preferred embodiment, the disorder is a wound. In another preferred embodiment the disorder is a damaged organ, e.g., an organ undergoing regeneration. The method includes administering an agent which increases the level of CTGF transcription.

An agent which increases the level of CTGF transcription can be one or more of: an agent which increases the level or activity of VEGF, e.g., a transition metal ion, e.g., manganese, cobalt, nickel, or combinations thereof; an agent which activates the VEGF receptor; an agent which increases PI3 Kinase activity; an agent which increases AKT kinase activity.

In a preferred embodiment, VEGF is increased. An agent which increases the level of VEGF activity can be one or more of the following; a small molecule, e.g., a transition metal ion; a peptide or protein, e.g., a monoclonal antibody, which stabilizes or assists the binding of VEGF to a VEGF receptor; a VEGF polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF polypeptide or functional fragment or analog thereof; an agent which increases VEGF nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF. In a preferred embodiment, VEGF levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF polypeptide or

functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF coding region; a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3'UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF protein is increased by increasing the level of expression of an endogenous VEGF gene, e.g., by increasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene is increased by: altering the regulatory sequence of the endogenous VEGF gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF gene to be transcribed more efficiently.

In a preferred embodiment, the VEGF receptor activity is increased. An agent which increases the level of VEGF receptor activity can be one or more of the following: an agent which activates a VEGF receptor, e.g., a monoclonal antibody which activates the VEGF receptor, e.g., a monoclonal antibody which activates a VEGF receptor in the absence of VEGF; a VEGF receptor ligand polypeptide (e.g., VEGF or placenta growth factor (PlGF)), or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof; an agent which increase VEGF receptor nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF receptor. In a preferred embodiment, VEGF receptor levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF receptor coding region; a promoter sequence, e.g., a promoter sequence from a VEGF receptor gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF receptor

gene or from another gene, a 3'UTR, e.g., a 3'UTR from a VEGF receptor gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF receptor protein is increased by increasing the level of expression of an endogenous VEGF receptor gene, e.g., by increasing transcription of the VEGF receptor gene. In a preferred embodiment, transcription of the VEGF receptor gene is increased by: altering the regulatory sequence of the endogenous VEGF receptor gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF receptor gene to be transcribed more efficiently.

In a preferred embodiment, PI3-Kinase is increased. An agent which increases the level of PI3-kinase can be one or more of the following: a small molecule which activates PI3kinase; a PI3kinase polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PI3kinase polypeptide or functional fragment or analog thereof; an agent which increase PI3-kinase nucleic acid expression, e.g., a small molecule which binds to the promoter region of PI3 kinase. In a preferred embodiment, PI3-kinase levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a PI3-kinase polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PI3-kinase coding region; a promoter sequence, e.g., a promoter sequence from a PI3 kinase gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PI3kinase gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PI3-kinase gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PI3kinase protein is increased by increasing the level of expression of an endogenous PI3-kinase gene, e.g., by increasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene is increased by: altering the regulatory sequence of the endogenous PI3 kinase gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator);

the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PI3-kinase gene to be transcribed more efficiently.

In a preferred embodiment, AKT is increased. An agent which increases the level of AKT can be one or more of the following: a small molecule which activates AKT kinase activity, e.g., the phosphoinositide PIP_2 ; a polypeptide, e.g., insulin, which stimulates activation, e.g., phosphorylation, of AKT; a AKT polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof; an agent which increase AKT nucleic acid expression; e.g., a small molecule which binds to the promoter region of AKT. In a preferred embodiment, AKT levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a AKT coding region; a promoter sequence, e.g., a promoter sequence from a AKT gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a AKT gene or from another gene, a 3'UTR, e.g., a 3'UTR from a AKT gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of AKT protein is increased by increasing the level of expression of an endogenous AKT gene, e.g., by increasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene is increased by: altering the regulatory sequence of the endogenous AKT gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the AKT gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is increased. An agent which increases Erk kinase activity can be one or more of: a small molecule which activates Erk kinase activity; an Erk polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding

an Erk polypeptide or functional fragment or analog thereof; an agent which increases Erk nucleic acid expression; e.g., a small molecule which binds to the promoter region of Erk. In a preferred embodiment, Erk levels are increased by administering, e.g., introducing, a nucleotide sequence encoding an Erk polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: an Erk coding region; a promoter sequence, e.g., a promoter sequence from an Erk gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from an Erk gene or from another gene, a 3'UTR, e.g., a 3'UTR from an Erk gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of Erk protein is increased by increasing the level of expression of an endogenous Erk gene, e.g., by increasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene is increased by: altering the regulatory sequence of the endogenous Erk gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the Erk gene to be transcribed more efficiently.

Another aspect of the invention features a method of screening for agents which increase or decrease fibrosis and/or angiogenesis to thereby treat disorders associated with increased or decreased fibrosis, e.g., the disorders mentioned above. The method includes: providing a cell, tissue, or subject, e.g., an experimental animal, e.g., an animal model for a fibrosis related disorder; contacting the cell, tissue or subject with a test agent; and determining whether the test agent inhibits a component of the VEGF signaling pathway.

In preferred embodiments, the screening can include screening for: an agent that inhibits VEGF activity; an agent that inhibits VEGFR signaling, e.g., an agent that inhibits the interaction between VEGF and a VEGFR; an agent that inhibits PI3 kinase activity; an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase; an agent that inhibits AKT activity; and/or an agent that inhibits ERK activity.

In some embodiments, the method can include one or more of the following steps:

applying VEGF to cells in culture, e.g., BREC or BREP; applying a candidate drug or a combinatorial library of drugs; assaying for levels of CTGF. CTGF levels can be assayed various methods commonly practiced in the art. In one embodiment, CTGF levels are assayed by Northern analysis for CTGF mRNA expression. In another embodiment CTGF levels are assayed by detect CTGF protein, e.g., with an antibody, e.g., using an ELISA assay or a Western blot assay. In another embodiment, CTGF transcription is monitored by assaying for a reporter protein, e.g., lacZ, chloramphenicol acetyltransferase (CAT), green fluorescent protein or variants thereof, and other fluorescent proteins and variants thereof, where the gene encoding the reporter protein is fused to the CTGF promoter and the ensemble is transfected into the cells. The methods can further include administering an agent identified by the screening methods described herein to an animal, e.g., an animal model for a fibrotic disorder.

Detailed Description

The inventors have discovered that VEGF can modulate the activity and/or expression of CTGF in a time- and concentration-dependent manner in cells and/or tissues with VEGF receptors, e.g., in endothelial cells, e.g., microvascular endothelial cells such as human retinal endothelial cells or bovine retinal endothelial cells (BREC), and in contractile cells, e.g., in capillary pericytes, e.g., in human or bovine retinal pericytes (BRPC). VEGF-induced modulation of CTGF can occur via the PI3 kinase pathway, e.g., via the KDR receptor-PI3 kinase-Erk pathway (e.g., in BREC), or the Flt1-PI3 kinase-Akt pathway (e.g., in BRPC). Modulation of CTGF via the VEGF pathway can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis-related disorders described herein.

VEGF receptor (VEGFR), e.g., Flt1 (VEGFR1), KDR/Flk1 (VEGFR2), Flt4 (VEGFR3), NP1, tie, or tie-2, can mediate increases in CTGF mRNA expression. The ability of Flt1 to induce increases in CTGF mRNA levels is demonstrated in the pericytes that have predominantly Flt1 receptors. In addition, placenta growth factor (PlGF), a Flt1 receptor-specific ligand, was able to induce CTGF mRNA levels in BRPC but not in BREC, indicating that VEGF can induce CTGF mRNA by activating through Flt1 in pericytes, e.g., BRPC. The KDR/Flk1 receptors in the endothelial cells can also induce CTGF gene expression since KDR/Flk1 receptors are the predominant VEGF receptors in endothelial cells.

The VEGF dose-response curves for CTGF in both BRPC and BREC are similar and

suggest that VEGF binds to high affinity receptors, consistent with the known Kd values of Flt1 and KDR/Flk1 at 10-100 pM. While not wanting to be bound by theory, VEGF-induced CTGF mRNA is most likely due to an induction of transcription rather than altering the half-life of CTGF mRNA since the addition of VEGF failed to change the degradation rates of CTGF mRNA. The time course of the action of VEGF on CTGF (which required 6-9 h) suggests this is potentially a chronic action of VEGF. In addition, the time needed to achieve maximum effect is also consistent with the calculated mRNA half-life of CTGF mRNA of 2-4 h. From a biological perspective, the effects of VEGF on CTGF mRNA could potentially have important physiological impact for several reasons. First, the increase in CTGF mRNA results in increased protein levels. Second, the VEGF concentration that was minimally active (0.25 ng/ml) can easily bind and activate a significant percentage of the VEGFR-1, -2 receptors. Third, this low level of VEGF may exist even in non-pathological states, suggesting that low levels of VEGF may have physiological actions on maintaining extracellular matrix production via the induction of CTGF. At 2.5-25 ng/ml VEGF which are encountered in hypoxic and angiogenic states (Aiello et al. (1994) N. Engl. J. Med. 331, 1480-1487), the induction of CTGF expression by VEGF could potentially induce the fibrosis that frequently accompanies neovascularization. This possibility is supported further by the demonstration that the protein levels of CTGF expression were increased 10 h after the addition of VEGF that was consistent with the maximum increase in the mRNA levels at 6-9 h. In addition, the potency of VEGF on CTGF expression appeared to be similar to TGF-beta1, suggesting that both of them could induce fibrosis associated with neovascularization.

The activation of the endogenous tyrosine kinases of KDR/Flk1s can stimulate multiple signaling pathways, including Ras-Erk, PI3-kinase-Akt, and phospholipase CK-PKC cascades. The results in BREC described herein indicate that VEGF can increase the tyrosine phosphorylation of KDR/Flk1 and its interaction with p85 subunit of PI3-kinase. In addition, VEGF also activates the Erk1/2 pathway in BREC. In contrast, VEGF was unable to activate Erk1/2 but stimulated the activation of PI3-kinase and phosphorylation of Akt in BRPC. These results indicate that the signaling pathways for Flt1 in vascular cells are different from those for KDR/Flk1. The lack of effect on Erk1/2 activation also supports the hypothesis that Flt1, unlike KDR/Flk1, is not involved in mitogenic actions.

The results described herein provide strong evidence that VEGF is inducing CTGF gene

expression in both endothelial cells and pericytes via VEGFR1 or -R2 by the activation of PI3-kinase and Akt. This evidence includes the ability of wortmannin, a PI3-kinase inhibitor, to inhibit the effects of VEGFs in both cell types. Adenovirus containing dominant negative mutants of p85 subunit of PI3-kinase or Akt inhibited the action of VEGFs, whereas overexpression of dominant negative mutants of Ras and Erk1 by adenovirus vectors did not inhibit CTGF mRNA expression. Conversely, the overexpression of constitutive active Akt increased CTGF mRNA expression by 2.5-fold. The overexpression of either the wild type or dominant negative of PKC isoform did not alter the effects of VEGF on CTGF mRNA levels.

In summary, the results described herein show that VEGF can induce the expression of CTGF via VEGFR, e.g., Flt1, KDR/Flk1, Flt4, NP-1, tie, or tie-2, by the selectively activated PI3-kinase-Akt pathway but mostly independent of the Ras-Erk pathway. In addition, the spectrum of signaling pathways can be different among different VEGFRs, possibly reflecting their physiological roles. These results support the conclusion that VEGF, through its effects on CTGF expression, has physiological roles such as the maintenance of capillary strength and wound healing via the extracellular matrix production. In disease states, VEGF-induced CTGF may cause the proliferation of fibrocellular components in retinal neovascular diseases such as proliferative diabetic retinopathy and age-related macular degeneration.

Modulation of CTGF through the VEGF pathway, e.g., modulation of components of the VEGF pathway, e.g., Flt1, KDR, Flt4, neuropilin-1, PI3 kinase, Akt, or Erk, can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis related disorders. CTGF has been associated with a number of fibrosis-related disorders, e.g., scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; renal disease; atherosclerotic plaques; inflammatory bowel disease; Crohn's disease; arthritic joints; cancer, e.g., invasive breast carcinoma, dermatofibromas, angioliipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture (J. Invest. Dermatol. 1996 106:729-733; J Biol Chem. 2001 276:10594-601; Int J Biochem Cell Biol. 1998 30:909-22; J Eur Acad Dermatol Venereol. 1998 11:1-8; Int J Biochem Cell Biol. 1998 Aug;30(8):909-22;

Ann Surg. 1999 Jul;230(1):63-71; J Cell Physiol. 1999 Oct;181(1):153-9; Curr Opin Nephrol Hypertens. 1999 Sep;8(5):543-8; J Am Soc Nephrol. 2001 Mar;12(3):472-84; J Rheumatol. 2000 Jan;27(1):149-54; J Mol Cell Cardiol. 2000 Oct;32(10):1805-19). Other fibrosis related diseases in which CTGF may be involved include macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments.

Generation of Fragments

Fragments of components of the VEGF signaling pathway, e.g., VEGF, VEGFRs, PI3 kinase, AKT, can be used to increase VEGF signaling, thereby increasing CTGF activity, thereby increasing fibrosis or angiogenesis. For example, various fragments of VEGF are known and described, for example, in U.S. Patent No.: 5,935,820.

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Random Methods

Amino acid sequence variants of a protein, e.g., a VEGF signaling pathway component described herein, can be prepared by random mutagenesis of DNA which encodes a protein or a

particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants, e.g., screening for CTGF modulating activity or VEGF signaling agonist or antagonist activity, are elsewhere herein.)

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, *Technique* 1:11-15). This is a very powerful and relatively rapid method of introducing random mutations. The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn^{2+} to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, *Science* 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA *in vitro*, and synthesis of a complementary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos.*

Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Directed Mutagenesis

Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (*Science* 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (*DNA* 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (*Proc. Natl. Acad. Sci.* (1978) USA, 75: 5765).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (*Gene*, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence.

Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants. For example, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Primary High-Through-Put Methods for Screening Libraries of Peptide Fragments or Homologs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, assembly into a trimeric molecules, binding to natural ligands, e.g., a receptor or substrates, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid (interaction trap) assays can be used to identify a protein that interacts with a component of the VEGF signaling pathway, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 kinase (e.g., p85), AKT, ERK. These may include agonists, superagonists, and antagonists of the components. (The subject protein and a protein it interacts with are used as the bait protein and fish proteins.). These assays rely on detecting the reconstitution of a functional transcriptional activator mediated by protein-protein interactions with a bait protein. In particular, these assays make use of chimeric genes which express hybrid proteins. The first hybrid comprises a DNA-binding domain fused to the bait protein. e.g., a VEGF or VEGFR

molecule or a fragment thereof. The second hybrid protein contains a transcriptional activation domain fused to a "fish" protein, e.g. an expression library. If the fish and bait proteins are able to interact, they bring into close proximity the DNA-binding and transcriptional activator domains. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site which is recognized by the DNA binding domain, and expression of the marker gene can be detected and used to score for the interaction of the bait protein with another protein.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homolog which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^{13} phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes recovered from a large excess of phage

lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

A common approach uses the maltose receptor of *E. coli* (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) *EMBO* 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) *Vaccines* 91, pp. 387-392), PhoE (Agterberg, et al. (1990) *Gene* 88, 37-45), and PAL (Fuchs et al. (1991) *Bio/Tech* 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) *Appl. Environ. Microbiol.* 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptides copies on the host cells (Kuwajima et al. (1988) *Bio/Tech.* 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the *Staphylococcus* protein A and the outer membrane protease IgA of *Neisseria* (Hansson et al. (1992) *J. Bacteriol.* 174, 4239-4245 and Klauser et al. (1990) *EMBO J.* 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull *et al.* (1992) *PNAS USA* 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to

the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89-1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^7 - 10^9 independent clones are routinely prepared. Libraries as large as 10^{11} recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an *in vitro* system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

In one application of this method (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251), a molecular DNA library encoding 10^{12} decapeptides was constructed and the library expressed in an *E. coli* S30 *in vitro* coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) *Anal. Biochem* 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screens

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the

desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest (e.g., VEGF or PI3 kinase) and a ligand (e.g., VEGFR and AKT, respectively) can be used to identify antagonists from a group of peptide fragments isolated through one of the primary screens described above.

Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine to perform for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics

The invention also provides for reduction of the protein binding domains of the subject polypeptides, e.g., VEGF or VEGFR, to generate mimetics, e.g. peptide or non-peptide agents. See, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP 0 412 762 and EP 0 031 080.

Non-hydrolyzable peptide analogs of critical residues can be generated using benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans* 1:1231), and β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Fusion Proteins

Polypeptides for modulating the level of a component of the VEGF signaling pathway can be fused to another protein or portion thereof. For example, a VEGF protein or antagonist or fragment thereof, can be operably linked to another polypeptide moiety to enhance solubility. Examples of a protein which can be fused with a protein or portions thereof include a plasma protein or fragment thereof, which can improve the circulating half life. For example, the fusion

protein can be a VEGF fragment-immunoglobulin (Ig) fusion protein in which the VEGF sequence is fused to a sequence derived from the immunoglobulin superfamily. Several soluble fusion protein constructs have been disclosed wherein the extracellular domain of a cell surface glycoprotein is fused with the constant F(c) region of an immunoglobulin. For example, Capon et al. (1989) *Nature* 337(9):525-531, provide guidance on generating a longer lasting CD4 analog by fusing CD4 to an immunoglobulin (IgG1). *See also*, Capon et al., U.S. Patent Numbers: 5,116,964 and 5,428,130 (CD4-IgG fusion constructs); Linsley et al., U.S. Patent Number 5,434,131 (CTLA4-IgG1 and B7-IgG1 fusion constructs); Linsley et al. (1991) *J. Exp. Med.* 174:561-569 (CTLA4-IgG1 fusion constructs); and Linsley et al. (1991) *J. Exp. Med.* 173:721-730 (CD28-IgG1 and B7-IgG1 fusion constructs). Such fusion proteins have proven useful for modulating receptor-ligand interactions and reducing inflammation *in vivo*. For example, fusion proteins in which an extracellular domain of cell surface tumor necrosis factor receptor (TNFR) proteins has been fused to an immunoglobulin constant (Fc) region have been used *in vivo*. *See, for example*, Moreland et al. (1997) *N. Engl. J. Med.* 337(3):141-147; and, van der Poll et al. (1997) *Blood* 89(10):3727-3734).

Antibodies

The invention also includes antibodies specifically reactive with a component of the VEGF signaling pathway described herein. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made as described herein by using standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).

A component of the VEGF signaling pathway described herein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the component using standard techniques for polyclonal and monoclonal antibody preparation. The full-length component protein can be used or, alternatively, antigenic peptide fragments of the component can be used as immunogens.

Typically, a peptide is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, a recombinant VEGF peptide, or a chemically synthesized VEGF peptide or antagonist. *See*, e.g., U.S. Patent No. 5,460,959; and co-pending U.S. applications USSN 08/334,797; USSN 08/231,439; USSN 08/334,455; and USSN 08/928,881

which are hereby expressly incorporated by reference in their entirety. The nucleotide and amino acid sequences of components of the VEGF signaling pathway described herein are known. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic VEGF preparation induces a polyclonal anti-VEGF antibody response.

Antibodies to a component of the VEGF signaling pathway, or fragments thereof, can be used to inhibit the levels of such a component, thereby decreasing CTGF activity. Examples of antibody fragments include F(v), Fab, Fab' and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.

Additionally, antibodies produced by genetic engineering methods, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used. Such chimeric and humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al., *Science* 240:1041-1043, 1988; Liu et al., *PNAS* 84:3439-3443, 1987; Liu et al., *J. Immunol.* 139:3521-3526, 1987; Sun et al. *PNAS* 84:214-218, 1987; Nishimura et al., *Canc. Res.* 47:999-1005, 1987; Wood et al., *Nature* 314:446-449, 1985; and Shaw et al., *J. Natl. Cancer Inst.* 80:1553-1559, 1988); Morrison, S. L., *Science* 229:1202-1207, 1985; Oi et al., *BioTechniques* 4:214, 1986; Winter U.S. Patent 5,225,539; Jones et al., *Nature* 321:552-525, 1986; Verhoeyan et al., *Science* 239:1534, 1988; and Beidler et al., *J. Immunol.* 141:4053-4060, 1988.

In addition, a human monoclonal antibody directed against a component of the VEGF signaling pathway described herein can be made using standard techniques. For example, human monoclonal antibodies can be generated in transgenic mice or in immune deficient mice

engrafted with antibody-producing human cells. Methods of generating such mice are describe, for example, in Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication WO 92/03917; Kay et al. PCT publication WO 93/12227; Kay et al. PCT publication 94/25585; Rajewsky et al. Pct publication WO 94/04667; Ditullio et al. PCT publication WO 95/17085; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol* 7:33-40; Choi et al. (1993) *Nature Genet.* 4:117-123; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur J Immunol* 21:1323-1326); Duchosal et al. PCT publication WO 93/05796; U.S. Patent Number 5,411,749; McCune et al. (1988) *Science* 241:1632-1639), Kamel-Reid et al. (1988) *Science* 242:1706; Spanopoulou (1994) *Genes & Development* 8:1030-1042; Shinkai et al. (1992) *Cell* 68:855-868). A human antibody-transgenic mouse or an immune deficient mouse engrafted with human antibody-producing cells or tissue can be immunized with a component of the VEGF signaling pathway described herein or an antigenic peptide thereof and splenocytes from these immunized mice can then be used to create hybridomas. Methods of hybridoma production are well known.

Human monoclonal antibodies against components of the VEGF signaling pathway described herein can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. *See, e.g.*, McCafferty et al. PCT publication WO 92/01047; Marks et al. (1991) *J. Mol. Biol.* 222:581-597; and Griffiths et al. (1993) *EMBO J* 12:725-734. In addition, a combinatorial library of antibody variable regions can be generated by mutating a known human antibody. For example, a variable region of a human antibody known to bind VEGF, can be mutated, by for example using randomly altered mutagenized oligonucleotides, to generate a library of mutated variable regions which can then be screened to bind to VEGF. Methods of inducing random mutagenesis within the CDR regions of immunoglobulin heavy and/or light chains, methods of crossing randomized heavy and light chains to form pairings and screening methods can be found in, for example, Barbas et al. PCT publication WO 96/07754; Barbas et al. (1992) *Proc. Nat'l Acad. Sci. USA* 89:4457-4461.

The immunoglobulin library can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library. Examples of methods and reagents particularly amenable for use in generating antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT publication WO 92/18619; Dower et al. PCT publication WO 91/17271; Winter et al. PCT publication WO 92/20791; Markland et al. PCT publication WO 92/15679; Breitling et al. PCT publication WO 93/01288; McCafferty et al. PCT publication WO 92/01047; Garrard et al. PCT publication WO 92/09690; Ladner et al. PCT publication WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *supra*; Hawkins et al. (1992) *J Mol Biol* 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc Acid Res* 19:4133-4137; and Barbas et al. (1991) *PNAS* 88:7978-7982. Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened to identify and isolate packages that express an antibody that binds a component of the VEGF signaling pathway described herein. In a preferred embodiment, the primary screening of the library involves panning with an immobilized component of the VEGF signaling pathway described herein and display packages expressing antibodies that bind immobilized a component of the VEGF signaling pathway described herein are selected.

Antisense Nucleic Acid Sequences

Nucleic acid molecules which are antisense to a nucleotide encoding a component of the VEGF signaling pathway described herein, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 Kinase, AKT, can be used as an agent which inhibits expression of the component. An "antisense" nucleic acid includes a nucleotide sequence which is complementary to a "sense" nucleic acid encoding the component, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule which antisense to the "coding region" of the coding strand of a nucleotide sequence encoding the component can be used.

The coding strand sequences encoding components of the VEGF signaling pathway described herein are known. Given the coding strand sequences encoding these components, antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).

Administration

An agent which modulates the level of expression of a component of the VEGF signaling pathway described herein can be administered to a subject by standard methods. For example, the agent can be administered by any of a number of different routes including intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal. In one embodiment, the VEGF signaling pathway modulating agent can be administered topically.

The agent which modulates protein levels, e.g., nucleic acid molecules, polypeptides, fragments or analogs, modulators, and antibodies (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically include the nucleic acid molecule, polypeptide, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition can be formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be

fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a VEGF polypeptide or anti-VEGF antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a

disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

The nucleic acid molecules described herein can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al., *PNAS* 91:3054-3057, 1994). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

The agent which modulates the activity of a component of the VEGF signaling pathway described herein can be administered by locally administration, e.g., topical administration. The agent can be applied once or it can be administered continuously, e.g., the agent is administered with sufficient frequency such that the affect on the VEGF protein level is maintained for a selected period, e.g., 5, 10, 20, 30, 50, 90, 180, 365 days or more. The administration of an agent which modulates, e.g., increases or inhibits, the level of a component of the VEGF signaling pathway described herein, e.g., a VEGF polypeptide or an anti-VEGF antibody, can also be repeated.

Transition Metals

Transition metal ions have been shown to enhance expression of the VEGF gene thereby increasing VEGF protein levels. See U.S. Patent No.: 5,480,975. Thus, in one aspect, a transition metal ion can be used to increase CTGF, thereby increasing fibrosis or angiogenesis, by increasing expression of VEGF.

The transition metals are the group consisting of the fourth, fifth and sixth levels of the periodic table and which fill the d orbital. They include such elements as Ni, Co, Mn, Zn, V, Cr, Fe, Cu, Mo, etc. The preferred candidate metal ions for use are manganese, cobalt and nickel.

Selection of other appropriate metal ions involves determining whether, and at what level, the ion will induce VEGF expression. Particularly for systemic applications, selection also involves a review of toxicity. Suitable techniques for those determinations are provided below in U.S. Patent No.: 5,480,795. Preferred ions are those with a substantial range between VEGF induction and toxicity.

The transition metal can be administered internally (systemic or local administration) in the form of a salt or free ion in a biologically compatible tablet or capsule, gel, or liquid, or it can be administered externally in the form of a biologically compatible powder, salve, liquid, or transdermal patch. Any physiologically acceptable anion such as chloride, sulfate, etc., can be included in the composition.

Appropriate release rates and dosages can be determined in order to affect the targeted tissue without substantial systemic effect. For example, these parameters can be determined as described in U.S. Patent No.: 5,480,795.

Gene Therapy

The gene constructs of the invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a component of the VEGF signaling pathway described herein. The invention features expression vectors for in vivo transfection and expression of a component of the VEGF signaling pathway described herein in particular cell types so as to reconstitute the function of, or alternatively, antagonize the function of the component in a cell in which that polypeptide is misexpressed. Expression constructs of such components may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation carried out in vivo.

A preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding a component of the VEGF signaling pathway described herein. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased

the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). A replication defective retrovirus can be packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include *Crip, *Cre, *2 and *Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al. (1992) cited supra). Furthermore, the virus particle is relatively

stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis *in situ* where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267).

Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39; Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a component of the VEGF signaling pathway described herein in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the subject gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. Other embodiments include plasmid injection systems

such as are described in Meuli et al. (2001) *J Invest Dermatol.* 116(1):131-135; Cohen et al. (2000) *Gene Ther* 7(22):1896-905; or Tam et al. (2000) *Gene Ther* 7(21):1867-74.

In a representative embodiment, a gene encoding a component of the VEGF signaling pathway described herein can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al. (1992) *No Shinkei Geka* 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).

In clinical settings, the gene delivery systems for the therapeutic gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *PNAS* 91: 3054-3057).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced in tact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

Cell Therapy

A component of the VEGF signaling pathway described herein can also be increased in a subject by introducing into a cell, e.g., an endothelial cell, fibroblast or a keratinocyte, a nucleotide sequence that modulates the production of the component, e.g., a nucleotide sequence encoding a component polypeptide or functional fragment or analog thereof, a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an

enhancer sequence, e.g., 5' untranslated region (UTR), e.g., a 5' UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3' UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence; or another sequence that modulates the expression of VEGF. The cell can then be introduced into the subject.

Primary and secondary cells to be genetically engineered can be obtained from a variety of tissues and include cell types which can be maintained propagated in culture. For example, primary and secondary cells include fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells (myoblasts) and precursors of these somatic cell types. Primary cells are preferably obtained from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells may be obtained for a donor (other than the recipient).

The term "primary cell" includes cells present in a suspension of cells isolated from a vertebrate tissue source (prior to their being plated i.e., attached to a tissue culture substrate such as a dish or flask), cells present in an explant derived from tissue, both of the previous types of cells plated for the first time, and cell suspensions derived from these plated cells. The term "secondary cell" or "cell strain" refers to cells at all subsequent steps in culturing. Secondary cells are cell strains which consist of secondary cells which have been passaged one or more times.

Primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous nucleic acid sequence which includes a nucleic acid sequence encoding a signal peptide, and/or a heterologous nucleic acid sequence, e.g., encoding a component of the VEGF signaling pathway described herein or an agonist or antagonist thereof, and produce the encoded product stably and reproducibly in vitro and in vivo, over extended periods of time. A heterologous amino acid can also be a regulatory sequence, e.g., a promoter, which causes expression, e.g., inducible expression or upregulation, of an endogenous sequence. An exogenous nucleic acid sequence can be introduced into a primary or secondary cell by homologous recombination as described, for example, in U.S. Patent No.: 5,641,670, the contents of which are incorporated herein by reference. The transfected primary or secondary cells may also include DNA encoding a selectable marker which confers a selectable phenotype upon them, facilitating their identification and isolation.

Vertebrate tissue can be obtained by standard methods such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. For example, punch biopsy is used to obtain skin as a source of fibroblasts or keratinocytes. A mixture of primary cells is obtained from the tissue, using known methods, such as enzymatic digestion or explanting. If enzymatic digestion is used, enzymes such as collagenase, hyaluronidase, dispase, pronase, trypsin, elastase and chymotrypsin can be used.

The resulting primary cell mixture can be transfected directly or it can be cultured first, removed from the culture plate and resuspended before transfection is carried out. Primary cells or secondary cells are combined with exogenous nucleic acid sequence to, e.g., stably integrate into their genomes, and treated in order to accomplish transfection. As used herein, the term "transfection" includes a variety of techniques for introducing an exogenous nucleic acid into a cell including calcium phosphate or calcium chloride precipitation, microinjection, DEAE-dextrin-mediated transfection, lipofection or electrophoration, all of which are routine in the art.

Transfected primary or secondary cells undergo sufficient number doubling to produce either a clonal cell strain or a heterogeneous cell strain of sufficient size to provide the therapeutic protein to an individual in effective amounts. The number of required cells in a transfected clonal heterogeneous cell strain is variable and depends on a variety of factors, including but not limited to, the use of the transfected cells, the functional level of the exogenous DNA in the transfected cells, the site of implantation of the transfected cells (for example, the number of cells that can be used is limited by the anatomical site of implantation), and the age, surface area, and clinical condition of the patient.

The transfected cells, e.g., cells produced as described herein, can be introduced into an individual to whom the product is to be delivered. Various routes of administration and various sites (e.g., renal sub capsular, subcutaneous, central nervous system (including intrathecal), intravascular, intrahepatic, intrasplanchic, intraperitoneal (including intraomental), intramuscularly implantation) can be used. One implanted in individual, the transfected cells produce the product encoded by the heterologous DNA or are affected by the heterologous DNA itself. For example, an individual who suffers from fibrosis is a candidate for implantation of cells producing an antagonist of a component of the VEGF signaling pathway described herein.

An immunosuppressive agent e.g., drug, or antibody, can be administered to a subject at a dosage sufficient to achieve the desired therapeutic effect (e.g., inhibition of rejection of the

cells). Dosage ranges for immunosuppressive drugs are known in the art. See, e.g., Freed et al. (1992) N. Engl. J. Med. 327:1549; Spencer et al. (1992) N. Engl. J. Med. 327:1541; Widner et al. (1992) N. Engl. J. Med. 327:1556). Dosage values may vary according to factors such as the disease state, age, sex, and weight of the individual.

Examples

Example 1: VEGF modulates CTGF mRNA Expression

The effects of VEGF on the expression of CTGF mRNA were studied by Northern blot analysis in BREC and BRPC. 25 ng/ml VEGF increased CTGF mRNA (~2.4 kb) levels in a time-dependent manner, reaching a maximum after 6 h in BREC (3.1 ± 0.70 -fold, $p < 0.001$) and after 9 h in BRPC (2.0 ± 0.22 -fold, $p < 0.01$).

The dose response to VEGF-induced CTGF mRNA expression was studied after 6 h of VEGF stimulation. The expression of CTGF mRNA was up-regulated in a dose-dependent manner, with significant increases observed at concentrations as low as 0.25 ng/ml in both BREC and BRPC. Maximal increases were observed at VEGF concentrations of 25 ng/ml in both BREC and BRPC.

Since BREC and BRPC may express both KDR and Flt1, we examined the effects of PlGF, a Flt1-specific ligand, on the induction of CTGF gene expression in vascular cells. CTGF mRNA levels were not affected after stimulation of 25 ng/ml of PlGF in BREC. In contrast, PlGF increased CTGF mRNA after 3 h of stimulation, which peaked after 9 h in BRPC (1.9 ± 0.30 -fold, $p < 0.01$), suggesting that VEGF-induced CTGF gene expression was mediated primarily by KDR in BREC and Flt1 in BRPC.

Example 2: VEGF Induction of CTGF Protein Production

To determine if the effects of VEGF on CTGF mRNA were correlated with its protein level, CTGF protein expression was assessed by Western blot analysis using anti-human CTGF antibody. The detected size of CTGF protein was ~38 kDa in both BREC and BRPC. VEGF (25 ng/ml) increased the level of CTGF protein after 10 h in both BREC and BRPC. Comparative studies were performed on the effects of VEGF (25 ng/ml) and TGF- β 1 (10 ng/ml) on the expression of CTGF mRNA and protein. VEGF and TGF- β 1 increased CTGF protein expression by a similar amount (2.5 ± 0.4 - and 2.8 ± 0.8 -fold, respectively, in BREC). CTGF

mRNA levels were also increased a similar extent (3.0 ± 0.3 - and 3.3 ± 0.5 -fold, respectively).

Example 3: Effects of VEGF on the Half-life of CTGF mRNA

The effects of VEGF on the stability of CTGF mRNA were examined. Northern blot analyses were performed with addition of actinomycin D ($5 \mu\text{g/ml}$) after 6 h of VEGF (25 ng/ml) stimulation. In BREC and BRPC3, the half-life of CTGF mRNA was 1.7 and 3.6 h, respectively. There was no significant difference between VEGF-treated and -untreated cells.

Example 4: Effects of Cycloheximide on CTGF mRNA Regulation

In order to examine the possibility that VEGF regulates CTGF mRNA expression through new protein synthesis of cytokines or transcription factors, cells were treated for 6 h with VEGF (25 ng/ml) and a protein synthesis inhibitor, cycloheximide ($10 \mu\text{g/ml}$). Cycloheximide did not prevent the increase of CTGF mRNA. Addition of both VEGF and cycloheximide increased CTGF mRNA 2.4 ± 0.41 -fold in BREC and 2.5 ± 0.40 -fold in BRPC after 6 h as compared with cycloheximide alone ($p < 0.01$). These data suggest that the stimulation of CTGF mRNA expression by VEGF was not induced by increased synthesis of a regulatory protein.

Example 5: Involvement of Erk and PI3-Kinase-Akt in VEGF Signaling

Since Erk and PI3-kinase-Akt pathways have been reported to play central roles in VEGF signaling and biological actions, it was investigated whether or not VEGF can activate Erk and PI3-kinase-Akt pathways equally in BREC and BRPC. Immunoblot analysis of immunoprecipitates of KDR from BREC stimulated with VEGF or PlGF using an antibody to phosphotyrosine and PI3-kinase p85 subunit demonstrated that VEGF, but not PlGF, promoted the tyrosine phosphorylation of KDR and interactions of KDR and p85 subunit of PI3-kinase. In contrast, Immunoblot analysis of immunoprecipitates of Flt1 from BRPC stimulated with VEGF or PlGF demonstrated that both VEGF and PlGF increased the tyrosine phosphorylation of Flt1 and interactions of Flt1 and p85 subunit of PI3-kinase. These data suggest that VEGF can activate the receptor tyrosine phosphorylation and interaction with PI3-kinase p85 subunit in both KDR and Flt1.

To investigate the activation of Akt and Erk, we next performed immunoblot analysis with anti-phosphorylated Akt or anti-phosphorylated Erk antibodies using total cell lysates from BREC or BRPC stimulated with VEGF. VEGF induced phosphorylation of both Akt and Erk in BREC by 3.1- and 5.8-fold, but only induced phosphorylation of Akt in BRPC by 2.6-fold. No effect on Erk phosphorylation was observed in BRPC. These data suggest that VEGF activated both Erk and PI3-kinase-Akt pathways in BREC, but stimulated only PI3-kinase-Akt pathway in BRPC.

Since the activation of PI3-kinase by VEGF has not been reported in BRPC, we studied the effects of VEGF on PI3-kinase activity in BRPC. The addition of VEGF (25 ng/ml) increased PI3-kinase activity in a time-dependent manner by 2.1 ± 0.27 -fold ($p < 0.01$) after 5 min and by 1.6 ± 0.17 -fold ($p < 0.05$) after 10 min in BRPC.

Example 6: Effects of PKC, Erk, and PI3-Kinase Inhibition on VEGF-induced CTGF Expression

To investigate the signaling pathways involved in VEGF-induced CTGF expression, the effects of inhibition of PKC, Erk, and PI3-kinase were determined. Cells were treated with 25 ng/ml VEGF for 6 h after pretreatment with the kinase inhibitor GF 109203X, a classical and novel PKC-specific inhibitor (1 μ M); PD98059, a MAPK/Erk kinase inhibitor (20 μ M); or wortmannin, a PI3-kinase inhibitor (100 nM). Neither GF 109203X nor PD98059 had significant effects on VEGF-induced CTGF mRNA expression, but wortmannin inhibited the effects of VEGF by $88 \pm 6.5\%$ ($p < 0.01$) in BREC and $78 \pm 22\%$ ($p < 0.01$) in BRPC. To confirm further the involvement of PI3-kinase in VEGF-induced CTGF expression, recombinant adenoviruses were used encoding dominant negative K-ras (DNRas), dominant negative extracellular signal-regulated kinase (DNErk), or Δ p85 of PI3-kinase. BREC were transfected with each adenoviral vector, followed by stimulation with 25 ng/ml VEGF for 6 h. Neither DNRas nor DNErk had significant effects on VEGF-induced increase in CTGF mRNA, but Δ p85 of PI3-kinase completely inhibited VEGF-induced CTGF expression ($p < 0.001$).

Example 7: Role of PKC ζ and Akt/PKB in VEGF-induced CTGF Expression

Since it has been reported that atypical PKC and Akt/PKB have significant roles as signaling molecules downstream of PI3-kinase, the involvement of PKC ζ and Akt in this process were examined. BREC were infected with each adenoviral vector, followed by

stimulation with 25 ng/ml VEGF for 6 h. Neither wild type PKC ζ nor dominant negative PKC ζ (DNPKC ζ) had significant effects on VEGF-induced increase in CTGF mRNA. In contrast, infection with constitutive active Akt (CAAkt) increased CTGF mRNA expression 2.1 ± 0.21 -fold ($p < 0.01$) without VEGF and 2.5 ± 0.40 -fold with VEGF. Overexpression with adenoviral vector containing dominant negative Akt (DNAkt) inhibited VEGF-induced CTGF expression by $85 \pm 13\%$ ($p < 0.01$).

Example 8: Methods

A) Materials-- Endothelial cell basal medium was purchased from Clonetics (San Diego, CA). Endothelial cell growth factor was purchased from Roche Molecular Biochemicals. Dulbecco's modified Eagle's medium and fetal bovine serum were obtained from Life Technologies, Inc. VEGF, placenta growth factor (PIGF), TGF- β 1, and anti-CTGF antibody were ordered from R & D Systems (Minneapolis, MN). Anti-KDR (Flk1) and anti-Flt1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A-Sepharose was purchased from Amersham Pharmacia Biotech. Anti-phospho-Erk, anti-Erk, anti-phospho-Akt, and anti-Akt were purchased from New England Biolabs (Beverly, MA). Anti-p85 and anti-phosphotyrosine were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Phosphatidylinositol (PI) was purchased from Avanti (Alabaster, AL), and PD98059, wortmannin, and GF 109203X were obtained from Calbiochem. All other materials were ordered from Fisher and Sigma.

B) *Cell Culture*-- Primary cultures of bovine retinal endothelial cells (BREC) and pericytes (BRPC) were isolated by homogenization and a series of filtration steps as described previously. BREC were subsequently cultured with endothelial cell basal medium supplemented with 10% plasma-derived horse serum, 50 mg/liter heparin, and 50 μ g/ml endothelial cell growth factor. BRPC were cultured in Dulbecco's modified Eagle's medium with 5.5 mM glucose and 20% fetal bovine serum. Cells were cultured in 5% CO₂ at 37 °C, and media were changed every 3 days. Cells were characterized for their homogeneity by immunoreactivity with anti-factor VIII antibody for BREC and with monoclonal antibody 3G5 for BRPC. Cells remained morphologically unchanged under these conditions, as confirmed by light microscopy. Only cells from passages 2 through 7 were used for the experiments.

C) *Recombinant Adenoviruses*— cDNA of constitutive active Akt (CAAkt, Gag protein fused to N-terminal of wild type Akt) was constructed as in Burgering et al. (1995) *Nature* 376, 599-602. cDNA of dominant negative Akt (DNAkt, substituted Thr-308 to Ala and Ser-473 to Ala) was constructed as described in Kitamura et al. (1998) *Mol. Cell. Biol.* 18, 3708-3717. cDNA of dominant negative K-Ras (DNRas, substituted Ser-17 to Asn) was kindly provided by Dr. Takai (Osaka University). cDNA of dominant negative extracellular signal-regulated kinase (DNERk, substituted Lys-52 to Arg in ATP-binding site) was constructed as described in Her et al. (1993) *Biochem. J.* 296, 25-3. cDNA of $\Delta p85$ was kindly provided by Dr. Kasuga (Kobe University). cDNA of PKC ζ was kindly provided by Dr. Douglas Ways (Lilly). cDNA of dominant negative PKC ζ (DNPKC ζ , substituted Lys-273 to Trp in ATP-binding site) was constructed as in Uberall et al. (1999) *J. Cell Biol.* 144, 413-425.

The recombinant adenoviruses were constructed by homologous recombination between the parental virus genome and the expression cosmid cassette or shuttle vector. The adenoviruses were applied at a concentration of 1×10^8 plaque-forming units/ml, and adenoviruses with the same parental genome carrying the *lacZ* gene or enhanced green fluorescein protein gene (CLONTECH, Palo Alto, CA) were used as controls. Expression of each recombinant protein was confirmed by Western blot analysis and increased about 10-fold compared with cells infected with the control adenovirus.

D) *Immunoprecipitation*— Cells were washed three times with cold phosphate-buffered saline and solubilized in 200 μ l of lysis buffer (1% Triton X-100, 50 mmol/liter HEPES, 10 mmol/liter EDTA, 10 mmol/liter sodium pyrophosphate, 100 mmol/liter sodium fluoride, 1 mmol/liter sodium orthovanadate, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 2 mmol/liter phenylmethylsulfonyl fluoride). After centrifugation at 12,000 rpm for 10 min, 1.0 mg of protein was subjected to immunoprecipitation. To clear the protein extract, protein A-Sepharose (20 μ l of a 50% suspension) was added to the cell lysates, after which they were incubated for 1 h, followed by centrifugation and collection of the supernatant. A specific rabbit anti-KDR or Flt1 antibody was added and rocked at 4 °C for 2 h; 20 μ l of protein A-Sepharose was then added, and the sample was rocked for another 2 h at 4 °C. For denaturation, protein A-Sepharose antigen-antibody conjugates were separated by centrifugation, washed five times, and boiled for

3 min in Laemmli sample buffer.

E) Western Blot Analysis-- Immunoprecipitated proteins or 30 µg of total cell lysates were subjected to SDS-gel electrophoresis and electrotransferred to nitrocellulose membrane (Bio-Rad). The membrane was soaked in blocking buffer (phosphate-buffered saline containing 0.1% Tween 20 and 5% bovine serum albumin) for 1 h at room temperature and incubated with primary antibody overnight at 4 °C followed by incubation with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). Visualization was performed using the enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech) per the manufacturer's instructions.

F) PI3-Kinase Assay-- PI3-kinase activities were measured by the *in vitro* phosphorylation of PI as in Xia et al. (1996) J. Clin. Invest. 98, 2018-2026. Cells were lysed in ice-cold lysis buffer containing 50 mM HEPES, pH 7.5, 137 mM NaCl, 1 mM MgCl₂, 1 mM CaCl₂, 2 mM Na₃VO₄, 10 mM NaF, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 5 µg/ml leupeptin, and 1 µg/ml pepstatin. Insoluble material was removed by centrifugation at 15,000 × g for 10 min at 4 °C. PI3-kinase was immunoprecipitated from aliquots of the supernatant with antiphosphotyrosine antibodies. After successive washings, the pellets were resuspended in 50 µl of 10 mM Tris, pH 7.5, 100 mM NaCl, and 1 mM EDTA. 10 µl of 100 mM MgCl₂ and 10 µl of PI (2 µg/µl) sonicated in 10 mM Tris, pH 7.5, with 1 mM EGTA was added to each pellet. The PI3-kinase reaction was initiated by the addition of 5 µl of 0.5 mM ATP containing 30 µCi of [γ -³²P]ATP. After 10 min at room temperature with constant shaking, the reaction was stopped by the addition of 20 µl of 8 N HCl and 160 µl of chloroform/methanol (1:1). The samples were centrifuged, and the organic phase was removed and applied to silica gel TLC plates developing in CHCl₃/CH₃OH/H₂O/NH₄OH (60:47:11:2). The radioactivity in spots was quantified by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

G) Amplification of Human CTGF cDNA Using Reverse Transcriptase-Polymerase Chain Reaction (PCR)-- cDNA templates for PCR were synthesized by reverse transcriptase (First Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech) from human fibroblast

according to the method recommended by the manufacturer. A standard PCR was performed (PCR optimizer kit, Invitrogen, Carlsbad, CA) using 5'-AGGGCCTCTTCTGTGACTTCG-3' (sense primer) and 5'-TCATGCCATGTCTCCGTACATC-3' (antisense primer). The PCR products were then subcloned into a vector (pCRII, Invitrogen) and sequenced in their entirety, and comparison with the published human sequences revealed complete sequence identity. This cDNA probe was used for hybridization.

H) Northern Blot Analysis— Total RNA was isolated using acid-guanidinium thiocyanate, and Northern blot analysis was performed. Total RNA (20 µg) was electrophoresed through 1% formaldehyde-agarose gels and then transferred to a nylon membrane. ³²P-Labeled cDNA probes were generated by use of labeling kits (Megaprime DNA labeling systems, Amersham Pharmacia Biotech). After ultraviolet cross-linking using a UV cross-linker (Stratagene, La Jolla, CA), blots were pre-hybridized, hybridized, and washed in 0.5× SSC, 5% SDS at 65 °C with 4 changes over 1 h. All signals were analyzed using a PhosphorImager, and lane loading differences were normalized.

I) Analysis of CTGF mRNA Half-life— CTGF mRNA half-life experiments were carried out using BREC and BRPC. The cells were exposed to vehicle or VEGF (25 ng/ml) for the indicated periods prior to mRNA stability measurements. Transcription was inhibited by the addition of actinomycin D (5 µg/ml). For inhibition of protein synthesis, cells were treated with cycloheximide (10 µg/ml) for the times indicated.

J) Statistical Analysis— Determinations were performed in triplicate, and all experiments were repeated at least three times. Results are expressed as the mean ± S.D., unless otherwise indicated. Statistical analysis employed Student's *t* test or analysis of variance to compare quantitative data populations with normal distributions and equal variance. Data were analyzed using the Mann-Whitney rank sum test or the Kruskal-Wallis test for populations with non-normal distributions or unequal variance. A *p* value of <0.05 was considered statistically significant.

All patents and references cited herein are hereby incorporated by reference in their

WO 02/07747

PCT/US01/22347

entirety.

We claim:

1. A method of decreasing fibrosis in a tissue of a subject, comprising:
identifying a subject in need of decreased fibrosis; and
administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
2. The method of claim 1, wherein the agent decreases the level or activity of VEGF or a VEGF receptor (VEGFR).
3. The method of claim 2, wherein the VEGFR is KDR, Flt1, Flt4 or neuropilin.
4. The method of claim 2, wherein the agent is selected from the group of: a VEGF binding or VEGF receptor (VEGFR) binding protein that inhibits VEGF binding to VEGFR; an antibody to VEGF or VEGFR that inhibits VEGF or VEGFR activity; a mutated VEGF or VEGFR or fragment thereof that inhibits VEGF signaling; a VEGF or VEGFR nucleic acid molecule that inhibits expression of VEGF or VEGFR; and a small molecule that inhibits transcription or activity of VEGF or VEGFR.
5. The method of claim 1, wherein the agent decreases the level or activity of AKT.
6. The method of claim 5, wherein the agent is selected from the group of: an AKT binding protein that inhibits AKT activity; an antibody to AKT that inhibits AKT activity; a mutated AKT or fragment thereof that inhibits AKT activity; an AKT nucleic acid molecule that inhibits expression of AKT; and a small molecule that inhibits transcription or activity of AKT.
7. The method of claim 1, wherein the agent decreases the level or activity of PI3 kinase.
8. The method of claim 7, wherein the agent is selected from the group of: a PI3 kinase binding protein that inhibits PI3 kinase activity; an antibody to PI3 kinase that inhibits PI3 kinase

activity; a mutated PI3 kinase or fragment thereof that inhibits PI3 kinase activity; a PI3 kinase nucleic acid molecule that inhibits expression of PI3 kinase; and a small molecule that inhibits transcription or activity of PI3 kinase.

9. The method of claim 7, wherein the agent is LY294002.
10. The method of claim 7, wherein the agent is wortmannin.
11. The method of claim 1, wherein the subject has a fibrosis related disorder.
12. The method of claim 1, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, or retinal tissue.
13. A method of decreasing angiogenesis in a tissue of a subject, comprising:
 - identifying a subject in need of decreased angiogenesis; and
 - administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
14. The method of claim 13, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, retinal tissue, or cancerous or tumor tissue.
15. The method of claim 13, wherein the agent is selected from the group of:
 - a) an agent that inhibits VEGF activity;
 - b) an agent that inhibits VEGFR signaling;
 - c) an agent that inhibits PI3 kinase activity;
 - d) an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that inhibits AKT activity; and
 - f) an agent that inhibits ERK activity.

16. The method of claim 15, wherein the VEGFR is KDR or Flt1.
17. A method of increasing fibrosis in a subject, comprising:
identifying a subject in need of increased fibrosis; and
administering to the subject an agent that induces a component of the VEGF signal transduction pathway, wherein the agent increases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
18. The method of claim 17, wherein the agent is selected from the group of:
a) an agent that decreases a PKC activity;
b) an agent that increases VEGF activity;
c) an agent that increases VEGFR signaling;
d) an agent that increases VEGFR interaction with p85 subunit of PI3-kinase;
e) an agent that increases PI3 kinase activity; and
f) an agent that increases AKT activity.
19. The method of claim 17, wherein the agent is VEGF or placental growth factor (PlGF)
20. The method of claim 17, wherein the agent is a transition metal ion.
21. The method of claim 18, wherein the VEGFR is KDR or Flt1.
22. A method of screening for a compound that decreases fibrosis or angiogenesis, comprising:
providing a cell, tissue, or subject;
contacting the cell, tissue, or subject with a test compound; and
determining whether the test compound inhibits a component of the VEGF signaling pathway.
23. The method of claim 22, further comprising contacting the cell, tissue, or subject with VEGF.

24. The method of claim 22, further comprising assaying the cell, tissue or subject for a CTGF activity.
25. The method of claim 22, wherein the cell is an endothelial cell
26. The method of claim 22, wherein the cell is a bovine retinal endothelial cell (BREC) or bovine retinal pericyte (BRPC).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

- (51) International Patent Classification⁷: **A61K 45/06**
- (21) International Application Number: **PCT/EP01/06976**
- (22) International Filing Date: **20 June 2001 (20.06.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP
- (71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).
- (71) Applicants and
(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished
upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/97850 A2

(54) Title: **COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)**

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

- 5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.
- 10 Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
- 15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
- 20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
- 25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).
- 30 The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-peri endothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).
- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; 10 Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I



I,

in which

r has the meaning of 0 to 2,


n has the meaning of 0 to 2;

R_3 und R_4

a) each independently from each other have the meaning of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one or more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.


25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranilic acid derivatives of general formula IV

30

11



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$

5

10

X

Y

p

 R^1

15

 R^2

20

 R^3

25

 R^4, R^5, R^6 and R^7

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning

of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or upto two of the groups R_a-R_f form a bridge witheach up to 3 C-atoms with R^1 or R^2 ,has the meaning of group $=NR^9$ or $=N-$,has the meaning of group $-(CH_2)_p$,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally

substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is

optionally substituted by one or more of halogen,

or is unsubstituted or substituted aryl or

heteroaryl,

has the meaning of hydrogen or C_{1-6} -alkyl, orform a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

has the meaning of monocyclic or bicyclic aryl or


heteroaryl which is unsubstituted or optionally

substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

independently from each other have the meaning

of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




- 15 V,
in which
R¹ has the meaning of group


20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$


in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions

- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.
- Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefor the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector
15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 receptor system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv)

specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in E. coli and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx.

200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of

treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

	mode of treatment	
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a

10 reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

15 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
modulate the biological function of one or several of the Angiopoietin/Tie
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I
which modulates the biological function of one or several of the VEGF/VEGF
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems
and comprising one or several agents as compound II which are targeted to
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I
which modulate the biological function of one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I
which are targeted to the endothelium via one or several of the VEGF/VEGF
receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

25

15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of general formula I

30

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,


25 30 whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

43

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

A

has the meaning of group $=NR^2$,

10


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20

44



5

m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

10

X

Y

p

15

R¹

20

R²

25

R³

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,has the meaning of group -(CH₂)_p,


has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,


has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,
 R⁴, R⁵, R⁶ and R⁷ independently from each other have the meaning
 of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl
 or C₁₋₆-carboxyalkyl, which are unsubstituted or
 optionally substituted with one or more of
 halogene, or R⁵ and R⁶ together form the group



R⁸, R⁹ and R¹⁰ independently from each other have the meaning
 of hydrogen or C₁₋₆-alkyl,
 as well as their isomers and salts,

and/ or a compound of general formula V




V,

in which


R¹ has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$


in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^6 is $-\text{CH}_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.
25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15 <140>
<141>

<160> 59

20 <210> 1
<211> 1835
<212> DNA
<213> Human

25 <400> 1

ttttacagtt ttccctttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccatat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
30 tatacaaaca gccaaaaaac cataatggtg ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaaccacac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
35 tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaacc ccaaaacgca acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
40 gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcggtt gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcgggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaag tcattcctta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaaccgca tcaggggcct ctcctcccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgetggctcc gagggggcat ccgcagtcgc tctggctgctc tcctcctgca 1440
50 ggctgggag ctggccacca cttctccgac tcgacccttc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctctttc tgctggtgct 1620
cttggacggg cgggtagtgc tgetgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
55 cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaagc ggcct

60 <210> 2
<211> 581
<212> DNA
<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
acactaaca cagctctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tggcccgtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttaggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

20 <400> 3

tagagatgtt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
25 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tcctgcgcat tgcaggctctg tgcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420
tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
30 atgaagttcc agagtgtgt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
35 <213> Human

<400> 4

cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
gggggtgcgtc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcaggtg 360
45 ctgctggca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggt cccatcagt 480
ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggtagacca 660
50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
agagcaccgt cagccagatc ttaccacaca cggtcgagtg ctctggacc tggccagca 900
acttctccac gaagcccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
55 gcacgtcagt gtgtcagcat ggcattcttc tcgttcgccc agcaacaagc ctgcagggag 1020
gtctgccacg cccgttctac cgcctgctg ccggcgggcc cagggtggag tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5
60 <211> 1015
<212> DNA
<213> Human

<400> 5
65

gaggataggg agcctggggg caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgct ttttgaaaat gttgaggttg aatgatggg aaccaacatt ctttggattt 120
 agtggggagc ataatagcaa acacccctt gggtcgcaca tgtacaggaa tgggacccag 180
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaaagt gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgag acaccccggt atgtcagcat cccccgacct 300
 10 gccttctggc ggcacctccc ggggtgctgt ttgagtcagc aggcattggg tgagagcctg 360
 gtatatgctg ggaacagggt gcaggggcca agcgttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatggtgc caggacaggt 480
 gtcccttcag tctctggtt atgacctcaa gtcctacttg ggccctgcag cccagcctgt 540
 gttgtaacct ctgcgtcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 15 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
 ctgggcaggg ttctctgtag aaccccgagg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagctc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgttctg ttatttcaact taaatcaaca tgctattttg ttttcaacta 900
 20 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgtca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

 <210> 6
 <211> 2313
 <212> DNA
 <213> Human

 <400> 6

 25 ccagagcagg cctggtggtg agcagggagc gtgcaccgga cggcggggtc gagcaaatgg 60
 gtctggccat ggagcacgga gggctctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcttc atcatcctgg 180
 ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cagagagtc aacctgcagg 240
 30 ccaccgagcg ccgagccgag ggcctataca ctacgctcct agggctcacg gcctcccagt 300
 ccaacttgac caaggagctc aacttcacca cccgcgcca ggatgccatc atgcagatgt 360
 ggctgaatgc tcgccgagac ctggaccgca tcaatgccag cttccgcccag tggcagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 atgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540
 35 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 ataaggaaag cgtgctgctg aacaaacgcg tggcgaggga acagctggtt gaatgctgta 660
 aaacccgga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720
 agccctctgc ctgccccttg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctcaa 900
 ggtggaggag ctggcccgga gcctccgggc ggatatcgaa cgctggccc gcgagaactc 960
 agacctccaa cgccagaagc tggaaagcca gcagggctg cgggcccagtc aggaggcgaa 1020
 acagaaggtg gagaaggagg ctacggccc ggaggccaag ctccaagctg aatgctccc 1080
 cgagaccag ctacgctgg aggagaaggc ggtgctgctg aaggaaacag acaacctggc 1140
 45 caaggagctg gaagagaaga agaggaggc ggagcagctc aggatggagc tggccatcag 1200
 aaactcagcc ctggacacct gcatacaagc caagtcgcag ccgatgatgc cagtgtcaag 1260
 gccatggggc cctgtcccca acccccagcc catcgaccca gtagccttg aggagtcaa 1320
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcgccggtt tgcggaggat 1440
 50 gcagggatat gctcacagcg cccgacacaa cccctcccgc ccgccccaa ccaccaggg 1500
 ccaccatcag acaactccct gcattgcaaac ccctagtacc ctctcacacc cgcaccgcg 1560
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacgct ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 55 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccaatgt cgacgtcaca catattaatg 1800
 tcacacagac gcgcgatgg catcacacag acggtgatga tgtcacacac agacacagt 1860
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920
 ccctttcaca cacactttct acccaattct cacttagtgt cagcttcccc cgacctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gcccagcac 2040
 60 ctcccctcct ccagcttctt ggcctccag ccacttctc acccccagtg cctggaccgg 2100
 gaggtgagaa caggaagcca ttcacctccg ctcttgagc gtgagtgtt ccaggacccc 2160
 ctcgggggccc tgagccgggg gtgaggggtc ctgttgctg ggaggggagc cactccttct 2220
 ccccaactc ccagccctgc ctgtggccc ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaatcct taaaaaaaaa aaaaaaaaaa aaa

 65 <210> 7
 <211> 389

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
<213> Human

15

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggtat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacaa aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggctcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatgggtg acaaactctgt gtgttatttc ttttctacct 180
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct taaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgata 480
40 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

<210> 10
<211> 1508
<212> DNA
<213> Human

45

<400> 10

50

cacaaacacg agagactcca cggctctgcct gagcacccgc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactc 240
gagctcaagc cagggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgc cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtcgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt cctctttttt gccttggtta tgggtgtacc ttccagccaa gggttgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccctagga actttgaaaa accaactag 720
catcattaat caggaatatt acagtaatga ggaatttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagttgg gatagtcttt 840
gctgtttgag gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctacagcta at ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtattgtt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 10 ttcattgtata ttgtacagtt acagtataat tcaaccttta ttttctaatt ttttcaaat 1320
 attgtttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa
 <210> 11
 <211> 389
 <212> DNA
 <213> Human
 15 <400> 11
 20 gggcaggtga tcagggcaca catttcccg ccatgagac agtagcattc cgggcaccca 60
 tcgtgccagc tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccagc 120
 aggatgggtg gccacgtga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaccacaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcgcccg cgaccacgct gggtagcca
 25 <210> 12
 <211> 981
 <212> DNA
 <213> Human
 30 <400> 12
 35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatctttctt 60
 tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggtgagg atcacttgag 120
 ccagaagt ttgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttgttgt ggctattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaatgtg tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cggttttaca gtgatcatat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaatatcat cacatgtacc aaaagctgac tcacctagtt 420
 40 taggataaca ggtctgcctg tttgaagatg aaaaataata ccattttaa atttgcccta 480
 ctcaatttcc ttctcagta cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaagggtga tatgccacca aaaccttttg ccaccttaaa aatttccttc aaagttaaaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 45 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgcta tccagagcca 900
 cactgcatct gcacccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960
 ataagagttc ttttgatgac g
 50 <210> 13
 <211> 401
 <212> DNA
 <213> Human
 55 <400> 13
 60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgcc 120
 tctctcccc agagcgaccc ccggggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggatcatca gcattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t
 65 <210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
10 tttgaaaatg ttaaatacaa gtccctattct ctttgtccag ctgggttttag cttagaggtag 180
ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaaagc caagttaact 240
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttactgtt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
tggtataaac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
15 tactgaaaac aatggtgcca tatgtctcaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaagga gtagtaacca agcttttctg cccaggaggt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
attcaataaa ccttagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
20 acaacaataa aagacacagt ccttctctc aaggtgttca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatc ttggttaggtc aggagtggga acccaaatc aattctttta 960
acaaacacta aaggtgatc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgaggtgggc caccctgtgc tggcttgaga tttttaaatg aggattacat taccctattt 60
ataatattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaacaacac tgccctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tttttaaaca ttttaaaaaa tgttagtggt tgtaagcac 240
caatcttaac tatttcacct gcccgggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagaggta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccttttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
50 atttaataat ggggtaatta cacaaagcgt aaaggatttt taaaaacaa gtattttttt 360
ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattagggac 480
caggtagata ttttctctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt ttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatttg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
gcatttttga ctctctcagg atcaaaaatac gagtctgcca actgtattaa atcctctctc 780
acccctccca ccagttgggt cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactgggt tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataaag tgtgtccttt ggaaacctgc tctgaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatgact ctgggaggat gctaattgca gagcctcaga ctggtggtac atctgatag 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgccactt tcagaggata 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtgccc tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaaagaagt aattcttcta actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctcgt gatttgcata 1620
 gttttctcag catttttgag agaggcacag ttttcacaat aatattgggt atcaccagta 1680
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740
 tcccggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 agtgttttca gaacagtaaa actcattagg aggactgcct atggtttttt cattcacaag 1860
 10 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040
 t

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccttc 60
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180
 25 tgggcccaga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

<400> 18

gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 35 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180
 accagattct agcaggttgg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtcctttgg gttgctttt attaatgagg agactattgt 300
 gatggcatat ctcttcacta tatttaatgc tttccaggga gtgttcattt tcacttttca 360
 40 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggg ctcccaactg agagtcoccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgtctcg tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagtg 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtg cacaaggggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggctg gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctccctctg taccaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtccccc aacagagact ctctttatag aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatgggtt tataatcccc attaacaaa 1380
 aaggggtgat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440
 aatcatacag tccagggaatt ccaagggcca catgcgagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtgggtctc 1560
 60 tgggtgtaaaa aagatgactg aaccttgtag ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcc 1680
 gccaggtatt ttaagattct gctgtggtt agagaaattg tgaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 tttgcagttc actgcaaactc ttttacatta aggcaaagat tgaaaacatg cttaaccact 1980

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctctt gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgtat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcaact tctcacaac 2460
 tttctagtga acaaaaggtg cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatattta gtaattaatt tattttatga taaagttcta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagtta acacggtttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

25 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaac aaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gtttctgtac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtgggccct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgta ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga ttagtggtat gtgcttctg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgccaagag ccagcatctg gacagtgtat ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagttgga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatcaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcggcgagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcatcatat gactggtacc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 tgccttttga gcaggcagag agcaacatga agcgtacg caagatcctc atgcaccaca 900
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgataggagg gccccagggt gcagggccaa ctctgaggag ttcatcccca 1020
 tctttgcaa taaccgcga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggcc 1140
 acgagaagga tcacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggtcgctt ctgcgacgtc ttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 60 tgggtgcagac cctggccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcgcggtg 1620
 accgagagga gaccacccgt atccgcagg agatccaaga gctcaaggcc agtccctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcgga agtgatgctg 1800
 65 actgcccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gccaggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggetgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcggaaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttgaaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

<210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacy gaatgccaaag gtccaagcca ggctcaagaa 120
 30 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttcccaaggg 180
 caaagggtact ttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttagggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactct ttagaagggt accattttgc actttaaagg 360
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540
 gtctgaccag ttcttggttaa caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaaccat tgggggaacc agtagaaaaa 660
 ggcagggtgc cctaattgtc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgcca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccattggattg cagtccctctc ctccagacca gctgcttatt tcctcagggg ccaggggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 55 cattagaaat aatgtataa aaataaataa gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360
 ccacaccaca gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag caggggttaca tggtaggaaa gaaaggaagt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt tttttcctca 660
 aatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttattttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaac catagcagcc ataaacagtg ctgggtcaaag 840
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa caggtcttag 900

	taaaaatctca	ctttttctect	actttttcatt	tcccaacccc	catgatacta	agtattttgat	960
	aagtaccagg	aaacaggggt	tgtaatagtt	ctaacttttt	ttgacaattg	ctttgttttt	1020
	tctaaacttg	taatagatgt	aacaaaagaa	ataataataa	taatgcccgg	ggctttatta	1080
5	tgctatatca	ctgctcagag	gttaataatc	ctcactaact	atcctatcaa	atttgcaact	1140
	ggcagtttac	tctgatgatt	caactccttt	tctatctacc	cccataatcc	caccttactg	1200
	atacacctca	ctgggttactg	gcaagatacg	ctggatccct	ccagccttct	tgctttccct	1260
	gcaccagccc	ttcctcactt	tgctttgccc	tcaaagctaa	caccacttaa	accacttaac	1320
	tgcatctgc	cattgtgcaa	aagtctatga	aatgtttagg	tttctttaaa	ggatcacagc	1380
	tctcatgaga	taacacccct	ccatcatggg	acagacactt	caagcttctt	tttttgtaac	1440
10	ccttcccaca	ggtcttagaa	catgatgacc	actccccag	ctgccactgg	gggcagggat	1500
	ggtctgcaca	aggtctgggtg	ctggctgggt	tcacttcctt	tgcacactcg	gaagcagggt	1560
	gtccattaat	gtctcggcat	tctaccagtc	ttctctgcca	acccaattca	catgacttag	1620
	aacattcgcc	ccactcttca	atgacccatg	ctgaaaaagt	ggggatagca	ttgaaagatt	1680
	ccttcttctt	ctttacgaag	taggtgtatt	taatttttagg	tcgaagggca	ttgcccacag	1740
15	taagaacctg	gatgttcaag	ggctctttga	gagggtctaaa	gctgcgaatt	ctttccaatg	1800
	ccgcagagga	gccgctgtac	ctcaagacaa	cacctttgta	cataatgtct	tgctctaagg	1860
	tggaacaaagt	gtagtcacca	ttaagaatat	atgtgccatc	agcagctttg	atggcaagaa	1920
	agctgccatt	gttcctggat	cccctctggt	tccgtgtttt	cacttcgatg	ttggtggctc	1980
	cagttggaat	tgtgatgata	tcatgatata	caggttttgc	actagtaact	gatcctgata	2040
20	tttttttaca	agtagatcca	tttccccgcg	aaacaccaca	tttatcaaac	ttcttttttg	2100
	agtctatgat	gcgatcacaa	ccagctttta	caca			
	<210>	24					
	<211>	1626					
25	<212>	DNA					
	<213>	Human					
	<400>	24					
30	ggacaatttc	tagaatctat	agtagtatca	ggatatattt	tgctttaaaa	tatatttttg	60
	ttattttgaa	tacagacatt	ggctccaaat	tttcatcttt	gcacaatagt	atgacttttc	120
	actagaactt	ctcaacattt	gggaactttg	caaatatgag	catcatatgt	gttaaggctg	180
	tatcatttaa	tgctatgaga	tacattgttt	tctccctatg	ccaaacaggt	gaacaaacgt	240
	agttgttttt	tactgatact	aaatgttggc	tacctgtgat	tttatagtat	gcacatgtca	300
35	gaaaaaggca	agacaaatgg	cctcttgtac	tgaatacttc	ggcaaaactta	ttgggtcttc	360
	atttctgtac	agacaggatt	tgactcaata	tttgtagagc	ttgcgtagaa	tggtattacat	420
	ggtagtgatg	cactggtaga	aatgggtttt	agttattgac	tcagaattca	tctcaggatg	480
	aatctttttt	gtctttttat	tgtaagcata	tctgaattta	ctttataaag	atgggttttag	540
	aaagctttgt	ctaaaaattt	ggcctaggaa	tggtaaacttc	attttcagtt	gccaaaggggt	600
40	agaaaaataa	tatgtgtggt	gttatgttta	tgttaacata	ttattaggta	ctatctatga	660
	atgtattttt	atatttttca	tattctgtga	caagcattta	taatttgcaa	caagtggagt	720
	ccatttagcc	cagtgggaaa	gtcttggaac	tcagggtacc	cttgaaggat	atgctggcag	780
	ccatctcttt	gatctgtgct	taaaactgtaa	tttatagacc	agctaaatcc	ctaacttggg	840
	tctggaatgc	attagttatg	ccttgtagca	ttcccagaat	ttcaggggca	tcgtgggttt	900
45	ggtctagtga	ttgaaaacac	aagaacagag	agatccagct	gaaaaagagt	gatcctcaat	960
	atcctaacta	actgggtcctc	aactcaagca	gagtttcttc	actctggcac	tgatgatcatg	1020
	aaacttagta	gaggggattg	tgtgtatttt	atacaaattt	aatacaatgt	cttacattga	1080
	taaaattctt	aaagagcaaa	actgcatttt	atttctgcat	ccacattcca	atcatattag	1140
	aactaagata	tttatctatg	aagatataaa	tggtgcagag	agactttcat	ctgtggattg	1200
50	cgttgtttct	tagggttcct	agcactgatg	cctgcacaag	catgtgatat	gtgaaataaa	1260
	atggattctt	ctatagctaa	atgagttccc	tctggggaga	gttctgggtac	tgcaatcaca	1320
	atgccagatg	gtgtttatgg	gctatttgtg	taagtaagtg	gtaagatgtg	atgaagtaag	1380
	tgtgttttgt	ttcatcttat	gaaaactctt	gatgcattgt	cttttgtatg	gaataaattt	1440
	tggtgcaata	tgatgtcatt	caactttgca	ttgaattgaa	ttttggttgt	atttatatgt	1500
55	attatacctg	tcacgcttct	agttgcttca	accattttat	aaccattttt	gtacatattt	1560
	tacttgaaaa	tatttttaaa	ggaaatttaa	ataaacattt	gatagttttac	ataataaaaa	1620
	aaaaaa						
	<210>	25					
60	<211>	1420					
	<212>	DNA					
	<213>	Human					
	<400>	25					
65	gttcagcatt	gtttctgctt	ctgaaatctg	tatagtacac	tggtttgtaa	tcattatgtc	60

5 ttcattgaaa tccttgctac ttctcttcc cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 tccttgctact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 480
 ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 10 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 aggggtggaga aagagggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atccttttgc tgggaggaga gttactcttg aaaggcaggg agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgccctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgtc 900
 15 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt tttttttaa 960
 gtggctttgt tttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 20 tatagaaaatt ttttatactg attgggttct agatggtcag ttttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgttg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaaataaa gtgtccctta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

35 aaacaaacaa aaaaaaagt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttccttttac tctgtctcac ctccttttag tgagtacttc 120
 cttaaaatag tgctaaacat acatatccgg aacttgaaag ctttgggttag ccttgcccta 180
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccatttagc 240
 cacttgctctc tgcaccattt atcacaccag gacaggggtct ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttccttgcaa gggctgtcct gtacctgcc gggcggccgc 360
 tcgaagcgtg gtcgcggccg aggtaactgaa aggaccaagg agctctggct gccctcagga 420
 attccaaatg accgaaggaa caaagcttca gggctctggg tggtgtctcc cactattcag 480
 40 gaggtggtcg gaggtaacgc agcttcattt cgtccagtcc ttccagtat ttaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaactatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattgggtggc accctgcttt gcctgtcctg ccaggacgag gcacctaca 120
 agccctaacc caggccccgc ccagggccac cacgaccact gcaaacaccg cacctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtacaggc tgaaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggtgctg 300
 tgggctgggt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

60 <210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctggtggg ctttccctc actgtcattg gaggcacatt 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgactca cctacttcca gttgtctggg gaggattacc gctggtggg 420
 10 gcgatctgtg ctgagtgttg gctccacggg cctcttcac ttcctctact cagttttcta 480
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagtctc tcggctactc 540
 cttactcact gggtatgtct tcttcctcat gctgggcacc atctcctttt tttcttccct 600
 aaagtctac cggtatatct atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgtctgt ctctcccttt cttcatgccc tgttgaactc toctaccagc ttctctctg 720
 attgactgaa ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataatctct atcacataag gattatata ttgaactttt 840
 taagttagct ttagttttgg tcctgatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 20 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 30 aggataaaag caccgctggg acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgt gaaggcaaag acgtcatcaa tgaaggtgtt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca actttagtatt 420
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccctgt tgacgaagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600
 ctccggtttt ctctcagatt cgtgtgaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattcttca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacggtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccaggaagta taagttggtg tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtga gaccttctcg taggacacgg tgagggcgag 1080
 ctcggtggg gagcggttta tgaccatcag gtccttcacg cgggtgctga gctggtcgat 1140
 45 gaacaggatg ggcaggtaat gcacggtttt ccccgactgg atcatcttca tgtaccgatg 1200
 cacatcggca ggcaggagg acccgtcaaa gacaaagtgt tccgcatca cgttcagcgc 1260
 cagcccggt cgccagtggg aactggtc atccagggca ctgctcggt tcttctccgc 1320
 ctgatctgc tgtgtatcag actcccggg gagcagggtt atttcttctg gcttggggac 1380
 catgtagggt gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 ccagcgtga tggaggaaga ttaggcata cagcgtccca ttgtttctcg ttttctttgg 1500
 tacagaaaca ttaactgtcc tttcaaatgg gactccaca tcaaagctct ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggcgcccgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcggtgtag acgatccgt acatgaccca gcaggtgtgc accacgtaga ccacgaacac 1740
 55 gccaccacc aagctggtga aggagctgc gccc

<210> 30
 <211> 1546
 <212> DNA
 60 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga ggggaattgt cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcaccat	ggaactgctt	caagtgacca	ttctttttct	tctgccagct	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caggtagtg	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
10	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtgggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	ttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgtttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaa	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcggt	cctaggaaaa	ggaattttag	1200
20	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tggtctcgct	gataggcatg	1260
	actttcctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tgttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgcaacgtg	tattattaaa	tattaggtag	aaatcatacc	atgctacttt	1440
	gtacatataa	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
25	aatactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
	<210>	31					
	<211>	750					
	<212>	DNA					
	<213>	Human					
30							
	<400>	31					
	cacttgggca	cccccathtt	ctaaaaaaat	ggaaatctgg	aggggcaaaa	aggtgtgctg	60
	aagggaagtg	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaatg	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaatttg	aaaatgcagt	cctgttttaa	acctttgatt	tacgactact	300
	tgtatagct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaaca	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactattttc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccatc	ggtcttgtaa	aaaggaagtc	tgaatacaga	gcccaaca	ctaaaattgt	600
	ttttctagct	acaaagtata	gcacatcaa	cacagacacg	atttggaact	cctgacaggt	660
45	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210>	32					
	<211>	1620					
	<212>	DNA					
50	<213>	Human					
	<400>	32					
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgcc	cagaaaaatc	tgtccttttt	ggtaccaaac	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aaagcttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttaga	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttacttta	ttccaggaca	420
	cgctggcatt	tggactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	ttcataatatt	tcacacaata	acagtccttt	cttatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccgag	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgcccctc	cccttggttt	tcaagtatct	660
65	tgaggttgtg	cacaaaaaatt	aggtcatgcc	ttcagtgctt	tgttctttta	acctaccctt	720
	tgacaatcag	gtgctaata	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

5 gtgttcctcc taggttgga gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaatga 900
 tgatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960
 tcgcaaatct gcccttatcg taagaacaag tttcagaatt tccctccac tatacgactc 1020
 10 cagtattatg tttacaatcc attggatgag tgcagcatta taagacctg gtgccagaa 1080
 aaatctgtcc tttttggtac caaacctgag gtcttttga agataatgta gaaaccact 1140
 acctattgaa ggcctgtttt ggctaactct tgcaaacctc gatgatacct gcttatgtgg 1200
 attcttttcc aactgctttt catttttaag tataaagact tagaaaacta gaataatgct 1260
 tttacaata attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
 15 atttaacaa gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aaccaacgc gtaaacagg gcagtatttg tgttccctaat tttaaaaagc 1440
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaaat gtgtaactta agggattat atataataat 1560
 acatatatac ctttgaacc tttatactgt aaataaaaaa gttgcttag tcaaaaaaaa 1620
 <210> 33
 <211> 2968
 <212> DNA
 <213> Human
 20 <400> 33
 25 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaacctga agaggaggag 60
 gagggaggaag aaggaggaaga agaagatgaa gaaagtgaag agggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgcagatga gaaggattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgatc ggactaaaga agaaagggct tatgacaaag caaacggag gattgagaaa 300
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 30 gtacttgggc atgtggacac agggagaca aaaattctag ataagctccg tcacacacat 420
 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccaccaa tgttccctct 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 35 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg atagggtata tgattggaag aagagtcctg actctgatgt ggctgctact 780
 ttaagaagc agaaaaagaa taaaaaagat gaatttgagg agcgagcaa ggctattatt 840
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttgggtacc tacctctgca catactggtg atggcatggg aagtctgatc 960
 40 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgaca ctgtgaagag 1020
 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttgatca atgggcggtt gaaggaagga gatacaatca ttgttccctg agtagaagg 1140
 cccattgtaa ctgagattcg aggcctcctg ttacctcctc ctatgaagga attacgagt 1200
 aagaaccagt atgaaaagca taaagaagta gaagcagctc aggggggtaa gattcttgga 1260
 45 aaagacctgg agaaaacatt ggctgggtta cccctccttg tggcttataa agaagatgaa 1320
 atccctgttc ttaaaagatga attgatccat gagttaaaagc agacactaaa tgctatcaaa 1380
 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
 gaatttctga aaacatcaga agtgccctat cgaggaatta acattggccc agtgcataaa 1500
 50 aaagatgta tgaaggcttc agtgatgtt gaacatgacc ctgagtatgc agtaattttg 1560
 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620
 atttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
 tacaagaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 atctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacggtggaa 1800
 55 gcaggtcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtttgt taaaaataga acctatccct ggtgagtcac ccaaaatgtt tggaagacat 1980
 tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040
 gactggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100
 gtatttgaaa tcatctaatt tttcacatg gacgaggaac tggagtaaat gcaatactgt 2160
 60 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
 gacttaagta tggaaggaag aaaaaatagg gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact gggttgacag tggtcagtta catgtcccca cagtccaat gtgctgttc 2340
 actcacctct cccttcccca acccttctct acttggtgc tgttttaag tttgcccttc 2400
 ccaaatttg gatttttatt acagatctaa agctotttcg attttatact gattaaatca 2460
 65 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttccac agtgattttt ccagattctt 2580
 tctgccatat gcctttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
 agttgtcttc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

accggggcgcc ggacgaccgc cactccttat cctccacgcc ccactcgac tcggagcggg 60
 accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcgggcc 120
 20 cggcttgagc cgagcgagc accccccgcg ccccgcgcca gaagtttggg tgaaccgggc 180
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctctgtgggt cggggtcgag cggccgcaga aggggcgggg 300
 tccgccccgc aggggagggc cccccggga cccgagaggg gggtagggac cgcgggctgc 360
 tgggtcgggc gcggcagcgt gtgccccgcg caggggaggg gccgccccgc tccccggccc 420
 25 gctgagagga ggaggcgagg gcggcgaggg aggatgtact tggtagcggg ggacaggggg 480
 ttggccgggt gcgggcacct cctggtctct ctgctggggc tgctgctgct gccggcgagg 540
 tccggcaccc gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
 aaccgccccg ggagcatcgt gcagggcgtc tgcggctgct gctacacgtg cgccagccag 660
 gggaacgaga gctgcgggcg cactctcggg atttacggaa cctgcgaccg ggggctgcgt 720
 30 tgtgtcatcc gccccccgct caatggcgac tccctcaccg agtacgaagc gggcgcttgc 780
 gaagatgaga actggactga tgaccaactg cttgggttta aacctgcaa tgaacacctt 840
 attgctgggt gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
 aatccccctt agtttccaag tcaggatatg tgcccttcag ctttaaagag aattgaagaa 960
 gagaagccag attgctccaa ggcccgtgtg gaagtcaggt tctctccacg ttgtcctgaa 1020
 35 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt accagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaacca 1200
 gttttcgggc tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac ttgccaaca 1320
 40 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
 cgcatagtct ctctgtggca tgggacacct ggaaagtgtg gtgatgtctt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
 cagtgtgggt agataaactg cgagaggtac tacgtgcccg aaggagagtg ctgcccagt 1620
 45 tgtgaagatc cagtgtatcc ttttaataat cccgctgggt gctatgccaa tggcctgatc 1680
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgtg gaaagtgcct 1800
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920
 50 cacaatgggt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
 caaggctgca ccttgaactg tcccttcggt ttccttactg atgccccaaa ctgtgagatc 2040
 tgtgagtgc cccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 cttgattgca tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
 55 tgcaagtgca gagaggcctc tgcttcagct gggccacca tctgtcggg cactgtctc 2280
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgct ctgatcacct gcccggtgcc tgctgtggc 2400
 aacccccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgag 2460
 aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
 60 ggagaaaagt ggaacattga ctctgtact cagtgcacct gccacagcg acgggtgctg 2580
 tgtgagacag aggtgtgccc accgctgctc tgccagaacc cctcacgcac ccaggattcc 2640
 tgctgcccac aggttacaga tcaacctttt cgcccttctt tgtcccgcaa taacagcgta 2700
 cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
 gacgtttgta ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgagtcctgc 2820
 65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgtcc ctactgcata 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgetactgcc tgcagggcca gacctctgc 3000
 tgcacgctca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagtgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 5 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaaatgat 3180
 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 caccgaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgctctctca ttataatagc attcctattc atcaatcaga agaacagtg gataccactg 3360
 ctttgctggt atcgaacacc aactaagcct tcttccttaa ataactcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccagggtg gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaaact agaatttggt cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttctc caagataaact gaccaagtgt tttcttagaa 3780
 15 ccaaagtttt taaagtgtct aagatatatt tgcctgtaag atagctgtag agatatgtg 3840
 ggtggggaca gtgagtttg atggggaaag ggggtggagg gtggtgttg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gccagagggt 3960
 tatttttttc ctattgctct gaagactgca ctgggtgctg caaagctcag gcctgaatga 4020
 gcaggaaaaca aaaaaggcct tgcgaccag ctgccataac caccttagaa ctaccagacg 4080
 20 agcacatcag aaccttttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgtagcgg catttctcta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 caatcaatca gccagtctct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggagg agagggtgac 4380
 25 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440
 ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tccctattat atactgattc taaaaaatag aaactacttc 4560
 attttaattg tatattatc aagcaccttt gttgaagctc aaaaaaatg atgcctcttt 4620
 aaacttttagc aattatagga gtatttatgt aactatctta tgcctcaaaa aacaaaagta 4680
 30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttcttg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 35 gtgtgtgcgc gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatlttga tttgctttca gttggttttc aatttgctca 5040
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100
 tttttttttt tcaaacaatg gtttgaaca actactggaa tattgtccac aataagctgg 5160
 aagtttggtg tagtatgcct caaatataac tgactgtata ctatagtgtt aacttttcaa 5220
 acagccctta gcacttttat actaattaac ccatttgctg attgagtttt cttttaaaaa 5280
 40 tgcttggtgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaag gaactttcaa gtattgttgt aaataacttg acagagggtg ctgaacttta 5400
 aaaaaaatta atttattatt ataataacct aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aaggtgttct agctgtttgc atcaaaggaa 5520
 45 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580
 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttacttttgt 5820
 50 tctgttgtgt ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880
 cacttgaggt gcatcatagt tctacagttt gttttgttt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60
 gccytcasgg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120
 65 gfkpcnenli agcniingkc ecentirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfsprcped svliegypapp geccpplsrc vcnpagclrk vcqpgnl nil vskasgkpge 240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrlt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpp kccdvfecvn dtkpacvfnn veyydgdnmfr mdncrfrcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceepit iitvdppacg elsnctlttrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlnpcpfg ltdaqnceic ecrprpkkr 540
 piicdkycpl gllknkhgdc icrcckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhkhknee shwdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfvveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdgpfr pslsrnnsvp nyckndegdi flaaeswkp d vctscicids 780
 viscfesescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldscthc 840
 yclqggtlcs tvscpplpcv epinvegsc pncpemyvpe ptnipiekt n hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsvd ckkgttrvqvd ssqrmrliae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

25 gcagtagctg gagggtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggcgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtcag agggatcagc cccagaacac accctcctcc ccgggacgccc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagattgag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaat ctccctgattc tccttatatg acctcaaaact gaccatacta aacagtgtag 360
 aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gactgtgaca 420
 gtcagtgtgg agtagacggg ttccctccacc caggggtgac tcaggggggat gatctgggtc 480
 ccattctggt cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctgttagt gtcgtaacct ctgtgtgcct cccgttacc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gcccagtaaa accaaagtca gggtaaccaa tgatcatttt caaaatgtta aaacccta 300
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcaact gactttaaga 60
 aaccataaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaagagtg ccagtgagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaaggcg acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaaatga acaaattacg gcaaagtgtt aggagaaaaga 360
 aggatgttta tgttcagag gccagtcgct cacaatcagt gcagacagat gaagaaggcg 420
 ttcgcaccgg aaaatgtagc ttcccggta agtaccttg ccatgtagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgctg taaaagatt gaaagctgaa aggaagtct 540
 tcaaggcgtt ctttggaaaa actggaaaaga aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
 25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctcccatc taatctcttt gatactcttg gaattctaat ctgaggagcg atttctgaat 180
 tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
 acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtatgag tataaaggcg atggaaattc 360
 30 tggctccttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
 tttttttgtt tttcacgaa tggaaaaatg atgtgttaagt ggtatagatt ttaatcagct 480
 aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaaatc tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
 atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

35

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaagt 60
 ctggttagtt tttgtaggct cattatggtt agggctcgta agatgtatat aagaacctac 120
 45 ctatcatgct gtatgtatca ctcattccat ttcatgttc catgcatact cgggcatcat 180
 gctaataatgt atccttttaa gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240
 ggtaaaaaaa attcccaaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
 acttccctca cagtgccgtg tctaccacta caaggactgt gcacttaagt aataattttt 420
 50 taagattcac tatatgtgat agtatgatat gcattttatt aaaatgcatt agactctctt 480
 ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
 gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaaac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaaattgaa 660
 actcagaact atattttctaa gcctgcattt tcatctatgc ataattttct tagtaatt 720
 55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
 ttaattttat gagaaggat tcttcatttt aattgctttt gggattactc cacatctttg 840
 tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900
 attggattga catatggttt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
 tgagatctat atttataagc agccatggaa ttcctattat gggatgttgg caatcttaca 1020
 60 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
 gtgagtttag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacctc 1140
 ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 tgaaaaaa

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagttagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
taacccccgg ctatcagtcg ggatggttgc caccctcctt gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttctctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
15 aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
ggaggaggga ggagctggta gggagatgct ggctttacct aaggctctga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gcccatTTTT gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaattct gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagtgtg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagttagc atttgggtgtg aaaaaaa

25

<210> 42
<211> 956
<212> DNA
<213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60
ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
cagggcgtgtg gcagccacac gcagggcgcc agggcgggcca gggacccaaa gcaggatgac 300
cacgcacctc cagcgcactg cctccccga atgcatttgg aaccaaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agecgtctgg acagatggac 420
40 gcaggccctg tccagccccc agtgcgctcg ttccgggtccc cacagactgc cccagccaac 480
gagattgtct gaaaccaagt caggccaggt gggcgggacaa aaggggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcgttgcc gcagcgggtg 600
gaaggaaagg cagatgtaa tgatgtgtt gtttacaggg tatatttttg atacctcaa 660
tgaatttaatt catagtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggcgg ggactgctgg ctacgcctcc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggt 900
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
<211> 536
<212> DNA
<213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggtttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
atTTTTTcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaag tgggttatgc caccTTTaaa accctttctg gtaaatatta tggtagctaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10

15

20

25

30

35

40

45

50

55

60

65

ggggaggggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctcccctggg caccaagtc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctctg gagggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttagggccag gacttggggc tccagctcat ctgttccttc tggggccatt 360
catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtggtgg gggctagtgg ggtttgaatt taggggccga 660
tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtatttc tgggtcccctt 720
ggaaatgtcc ccttcttcag tgtcagacct cagtcccagt gtccatatcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggt 840
gccagtgac ctgggggagc ctgggtgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt cttagagggtc agaattattg cttcaggatc agctgggggt 1020
atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgtt agatctggaa cccccaagtg 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
aaagagtgc cttagagggc tccttgggcc tcagggaatgc tcctgctgct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgataggt gactatattt accaaagccc ctacctgctg 1320
ctgggtccct tgtagcacag gagactgggg ctaaggggcc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgctg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgttctctg cattcatctg 1620

<210> 45
<211> 169
<212> DNA
<213> Human

<400> 45

tcttttgcctt ttagcttttt atttttgtat taacaggagt cttattacac ataggctctga 60
taaaactggg ttatgatctt cagtctgatt ccagtgtgctc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttgggaaga cttagtgtga

<210> 46
<211> 769
<212> DNA
<213> Human

<400> 46

tgcagggtcat atttactatc ggcaataaaa ggaagcaaa cagtattaag cagcgggtgga 60
atttgcctgct ttacttttt ataaagtgtc acataaaaatg tcatatttcc aaatttataa 120
acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aagggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc ttcttgata gtctgtattt gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgagggt 600
ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

10 tttagtccat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
gtgaaaatta gtgactgggt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
ggatgggtgg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15 gccttactta gtccttgcca gaggttgagt ggggacctac gaggttcaaa atcaaattggc 360
atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
tggtgctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtccct ctctccctcc 540
actagtgtgg gccactgcac tgaggggggt gccaccaatt ctctctagag aagagacact 600
20 ccagaggccc ctgcaacttt cgggatttcc agaagggtgat aaaaagagca ctcttgagtg 660
gggtgccagg aatgttttaa atctatcagg cacactataa agctggtggg ttcttctctac 720
caagtggatt cggcatatga accacctact caatacttta tttttgtct gtttaaacac 780
tgaactctgg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840
ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
25 gcaatagatg gggcttccca ccatttgttg gttattgctg gggtagcca ggagcagtg 960
ggatggcaaa gtaggagaga ggccagagg aaagccatc tccctccagc tttgggtct 1020
ccagaaagag gctggttttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
aggatgaacag tccctacctgc ttggtacctt agtccctcaa taagattcag aggaagaagc 1140
30 ttatgaaact gaaaatcaaa tcaaggtatt gggaagaata attcccctc gattccacag 1200
gaggaagac cacacaatat cattgtgctg gggctcccca aggcctgcc acctggcttt 1260
acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
caaggagttt tcagggaact ctatcaagcc atacaaaat cagggtcaca tgtgggtttc 1380
ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcat 1440
35 gcagttgggc tgacctgaca aagccccag tttcctgttg caggttctgg gagaggatgc 1500
attcaagctt ctgcagccta ggggacagg ctgcttgttc agttattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
agggagaaa gctatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccaggaaa ccaggaaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
gggggagtg gagggggaag aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
ctctatctga ggagcccca ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
tgaaaatttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100
45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
gcagaactgg ctgaaacaag atttcatggg gtcaaccatg agagatgact caatgccaaag 2220
gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggct 2280
tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atccactga 2340
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
ggggtgtcc

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattha cacacctgac 120
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccaggc ccgtttttcca tccctaagta ccattctctc atttggggcc ttctaggggt 240
65 gggggccctga gcttgggttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttctttt ttttcctcga 480
 gacggagctt cgctgtgttg cccaggctgg agtgacgtgg cacgggtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc ctcccgagta gctgggacta 600
 taggtgcca ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctgg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcttggtt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgcttc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtgaagc cagcctttgg ggcaggaaac cagctcagag 1020
 aggctacca gctcagctgc tggcaggagc caggatatta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaagtc 1380
 tcagatcgat gtatttctct ccctggtctc ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggetgagg cgggaggatt gcttgagccc aggagttgga 60
 tgttgcaagt agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcgggtta cgggaaaacc 180
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttg 240
 tcccgggagg cttttctcca acagtgtgac accagaccgc ccatgggaac cctggccaca 300
 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 35 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420
 tgcgtgcctg tgtgtgtgct tgccccctcc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cactgagac tgcccagaga cagcagact 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 caggtgctaa atgacccgac atgcattacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtga cctgccccg tggcgtctca cggtagtgc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840
 tactttgacc tcttgctac aaccccttc ttgggtcga ggtggttagc tttgttact 900
 45 tcagatggtt gggggcggtt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt ctagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgata cactactaat gatcctcgt 240
 cactgtgtgc attgtcatca ttccatggcc ttactttccc tctcagcgc atttgcata 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60

<210> 51

<211> 1191

<212> DNA

<213> Human

65

<400> 51

5 ctagcaagca ggtaaaccgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa aactcagtg tgttggtctt ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gtttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcgga gacgctcctg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaga gcggttttct ccctgcttct cttctgtcac 420
 ccccgctcct ctccccagg aggtccttgg atttatggta gctttggact tgcttccccg 480
 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
 10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagtctgt 1080
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140
 20 atgggcaaaa gtccagtgtg ttcagtaaag tgctaatac aagttggagg t

 <210> 52
 <211> 1200
 <212> DNA
 25 <213> Human

 <400> 52

 30 aacagggact ctactctat caacccagc ctggagtcg gtgcgcccac cctgggtccc 60
 tgcaaccctc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacaggggtt 180
 cgccttctgt ccaggccggc atcatatact ttaaatcatg ccagatgac tttaatacct 240
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 accaacctta atgctatgta aatagttgtt atactgttg ttaacaacag tatgacaatt 360
 35 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtg tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagt aaagttagg tacagtggaa agagtgttg aaaacataaa catttggacc 600
 tttcaagaaa ggtagcttgg tgaaattttt caccctcaaa ctatgtccca gtcagggtc 660
 40 tgctactaat tagctataat ctttgcaaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggctact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattccatc tgtgttaact gtatgagtca aactgaaaa 840
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960
 45 agagatgggg tctcactctg tcaccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgatc ctctgcctc tgcctccaga gtagctgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

 50 <210> 53
 <211> 989
 <212> DNA
 <213> Human

 55 <400> 53

 60 aagccaccac tcaaaaactc ctatacattt tcacagcaga gacaagtga catttatttt 60
 tatgcctttc ttcctatgtg tttttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc cagggagcct ctacaaatgc 180
 agagtgactc tttaccaaca taaacctag atacatgcaa aaagcaggac ccttcctcca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300
 cgactgtgat agagggtgct acatgaacat gctactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc attctcctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

5 cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
 ttaataattat tcttttctca ttcccatctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgtc ctgtcgccca gcgggagtg c actggcgcaa 960
 gcccggtca ccgcaatctc tgccacccg

10 <210> 54
 <211> 250
 <212> DNA
 <213> Human

15 <400> 54
 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcatctggg aacccacacc ttgatccaag agctagggaa 240
 acttcagttg

20 <210> 55
 <211> 2270
 <212> DNA
 25 <213> Human

<400> 55

30 gcgccccga gcagcgccc cgcctccgc gccttctccg ccgggacctc gagcgaaaga 60
 ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacaccgg ccgccacccc 120
 gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgctcgcccg 180
 ctgccccggg gctactcctg cgcgccaaa tgagctccc catcgccagg gcgctgcct 240
 tagtcgtcac ccttctccac ttgaccaggc tggcgctctc cacctgcccc gctgcctgcc 300
 actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
 35 gctgtgttaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
 accacaccaa ggggttgaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
 gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540
 aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 ttctctgtg tcccaagaa ctatctctcc ccaactggg ctgtcccaac cctcggtg 660
 40 tcaaaagttac cgggcagtcg tcgcgaggag gggctgtgta cgaggatagt atcaaggacc 720
 ccattggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaagagg cagctcactg aagcggctcc 840
 ctgtttttgg aatggagcct cgcctctat acaaccctt acaaggccag aaatgtattg 900
 ttcaaaacac ttcatggtcc cagtgtctaa agacctgtg aactggtatc tccacacgag 960
 45 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccggtttgt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 aatcccccca accagtcagg ttacttacg ctggatgttt gagtgtgaag aaataccggc 1140
 ccaagtactg cggttcctgc gtggacggcc gatgtgcac gcccagctg accaggactg 1200
 50 tgaagatgag gttccgctgc gaagatggg agacattttc caagaacgct atgatgatcc 1260
 agtccctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
 ggtgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
 cctagacaaa caaggggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggt 1440
 ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
 ggtatttcga aactgccaa ggtgctgggt cggatggaca ctaatgcagc cagcattgga 1560
 55 gaatactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
 ttgatgactt tctgttttct gtttctaagt taatttctaa gcatattttc tctaggcttt 1680
 tttccttttg ggttcttaca gtcgtaaaag agataataag attagtgtga cagtttaaag 1740
 cttttattcg tcctttgaca aaagtaaagt ggagggcatt ccatcccttc ctgaaggggg 1800
 aactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 60 ggtgttttaa gactgaatgt tttattttatc aaaatgtagc ttttggggag ggaggggaaa 1920
 tgtaatactg gactaatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
 tatggaatta accatttaaat aaagaaatat ttacctataa tctgagtgtg tgccattcgg 2040
 tatttttaga ggtgtcccaa agtcattagg aacaacctag ctacagctact caattattca 2100
 aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
 65 ttataccttc agtagagaaa agtcttttga tataaagtaa tgtttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga tcttgaagct aaaaaaaaaa

<210> 56
<211> 1636
<212> DNA
5 <213> Human

<400> 56

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
tggtttgctt ggtctcaagg acaactgcatc gtcaaaactga tccccctggcc gttggaggag 240
cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420
gatgtctctt gcctgggttct tgctacggga ctcaacgatg ggagatcaa gatctgggag 480
gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
tcgggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
agcagtgttg tctcttgatg cttctcccc gactctggcc tgcttgctac ggcttcttac 840
gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggtc actccaccac 900
25 acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
tggggccctg aactgaaaac tcccattgca tttgtctcta tgaccaatgg gctttgctgc 1080
acattttttc cacatgggtg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
tggcagctc ctagggtctc gtctcactg aagcacttat gccggaaaag ccttcgaagt 1200
30 ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
acatacagga ctttttaagc aacaccacat ctgtgtcttc tttgtagcag ggtaaatcgt 1320
cctgtcaaag ggagttgctg gaataatggg ccaaaccatct ggtcttgcat tgaatatgca 1380
tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
ttttgtctt taaatagata caaatgtcta tcaactttta tcaagttgta acttatattg 1500
aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
gaccctgtgc tgcgtt

<210> 57
<211> 460
40 <212> DNA
<213> Human

<400> 57

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaagagaa gacaaaagaa 120
tggaaatgagc taaagcagcc gcctgggggtg ggaggccgag ccattttgta tgcagcaggg 180
ggcaggagcc cagcaaggga gcctccattc ccaggactct ggaggagact gagaccatcc 240
50 atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
aactgaggct gggaagtac atagcaagtg actggcagag ctgggactgg aaccaacca 360
gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
ccgagctcga attcgtaatc atggtcatag ctgtttcctg

<210> 58
55 <211> 1049
<212> DNA
<213> Human

<400> 58

60 atctgatcaa gaatacctgc cctgggtcact ctgcggatgt ttctgtccac ttgttcacat 60
tgaggaccaa gatatacttt ttacagagg cacttggtcg gtctaacaca gacacctcca 120
tgacgacatg ctggctcaca ttttgagtt ctgcagaagt cccctccca gcctggacta 180
cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gactctgaa 240
65 gtcagtgtct gtgcagggtg taccgtggct ctgcattcct caggcattaa aggtctttt 300
ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360

5 aaaatgtaaa cttcacctag ttcattctt ccaaatccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggacttttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtatata aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccggt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaataata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttggttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctoacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctgggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgccaattta gtagtaatat cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.